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Abstract: Iron is an essential nutrient critical for oxygen transport, DNA synthesis, ATP 
generation, and cellular proliferation.  At the molecular level, insufficient iron elicits a 
cascade of cellular events aimed at conserving iron for the maintenance of these life-
preserving functions, but tissue-specific responses and metabolic adaptations to iron 
deficiency (ID) are not fully understood.  Recently, small regulatory RNA molecules 
called microRNA (or miRNA) have been identified as an important mechanism for 
regulating various cellular processes.  Therefore we sought to determine if the expression 
pattern of miRNA changes in response to dietary ID and to examine the potential 
regulatory capacity of miRNA in the adaptive response to ID.  To do this, we first 
characterized the expression of miRNA in the livers of iron-sufficient and iron-deficient 
animals using next-generation sequencing technology.  Results compiled from three 
different bioinformatics approaches indicate that ~10 miRNA are differentially expressed 
in the livers of ID rats.  Further bioinformatics analyses suggested that at least two of 
these miRNA, miR-210 and miR-181d, had predicted targets directly involved in either 
the maintenance of iron homeostasis or the metabolic adaptation to iron deficiency.  We 
then used reporter assays to validate the putative miRNA targets including the miR-210 
target, cytoglobin, and the miR-181d targets, carnitine palmitoyltransferase 1B and 
mitoferrin 1.  These findings have provided insight into the metabolic adaptation to ID 
and have demonstrated how miRNA contribute to the molecular coordination of iron 
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Iron is an essential, yet potentially toxic nutrient; thus iron homeostasis must be 
tightly regulated to ensure adequacy and prevent overload.  Iron balance is maintained by 
two regulatory systems that function to coordinate iron homeostasis at both the systemic 
and cellular levels.  While the machinery controlling these two systems is different, there 
is considerable overlap in the molecular components that each of these systems control, 
and as such both must function synergistically to coordinate vertebrate iron metabolism.  
Yet, many questions remain as to how these systems communicate with one another, 
particularly in situations where iron availability is altered and iron homeostasis is 
disrupted.  
 Central to the potential for iron to accumulate and promote cell damage through 
the production of free radicals is the absence of a regulated mechanism to promote iron 
efflux from the body.  Systemic iron homeostasis is tightly maintained through the 
regulation of intestinal iron absorption and recycling of iron from specialized cells that 




hormone hepcidin is primarily responsible for coordinating systemic iron homeostasis by 
affecting the rate of intestinal absorption and/or iron release from cells of the RES [1].  When 
hepatic iron stores are elevated, hepcidin expression, synthesis, and secretion is increased to 
regulate systemic iron metabolism.  Hepcidin represses cellular iron export by binding to the 
iron export protein ferroportin (Fpn) and promotes Fpn internalization, ubiquitination, and 
subsequent proteasomal degradation [1, 2].  Thus, with elevated iron stores, iron is retained 
within enterocytes and the iron-recycling macrophages of the RES thereby limiting iron 
absorption and release from iron stores.  Conversely, when iron stores are low, hepcidin 
expression is suppressed and intestinal iron absorption and iron release from the 
macrophages of the RES is enhanced in an effort to restore iron homeostasis [2]. 
While hepcidin is generally considered to be the primary means of regulating 
systemic iron homeostasis, a family of cytosolic RNA binding proteins known as Iron 
Regulatory Proteins (IRP) is considered to be the global regulators of cellular iron 
homeostasis.  IRP regulate cellular iron homeostasis by “sensing” intracellular iron status and 
coordinating the uptake, storage, and utilization of iron accordingly.  The two members of 
this family of RNA binding proteins include IRP1 and IRP2, both of which coordinate 
cellular iron homeostasis through high-affinity binding to stem-loop structures known as Iron 
Responsive Elements (IRE) in either the 5’ or 3’ untranslated region (UTR) of mRNA 
encoding proteins involved in iron metabolism. These highly conserved stem-loop structures 
are present in mRNA encoding proteins of iron uptake (transferrin receptor 1, or TFRc and 
divalent metal transporter 1, or DMT1), iron storage (heavy or H- and light or L-ferritin), 
iron utilization (mitochonodrial aconitase or, ACO2), and iron export (ferroportin, or FPN) 
[3].  When cytosolic iron levels are limiting, IRP bind to IRE with high affinity thereby 
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inhibiting the translation of mRNA containing 5’ IRE, such as ferritin, or stabilizing mRNA 
containing 3’IRE, such as TFRC [3].  Conversely, with elevated cytosolic iron levels, IRP 
lose their high-affinity RNA binding activity resulting in the de-repression of ferritin 
synthesis and degradation of TFRC mRNA [3, 4]. 
While IRP1 and IRP2 both possess the same RNA binding function, they are 
regulated through distinct iron-dependent mechanisms.  IRP1 is a bifunctional protein that 
can exhibit either high-affinity RNA binding activity (apoIRP1) or enzymatic activity by 
functioning as the cytosolic isoform of the tricarboxylic acid cycle enzyme aconitase (c-acon 
or holoIRP1) [3, 4].  Under iron-replete conditions, the formation of a [4Fe-4S] iron-sulfur 
cluster is favored and is associated with a reduction in high-affinity RNA binding activity 
and subsequent increase in enzymatic activity of c-acon [5].  However, when iron is limiting, 
formation of the Fe-S cluster is impaired (or the cluster is disassembled) and holoIRP1 is 
converted to its active high-affinity RNA binding form (apoIRP1) [3-5].   
Despite an approximate 61% amino acid identity and 79% amino acid similarity, 
IRP2 lacks the cysteine residues required to coordinate a [4Fe-4S] iron-sulfur cluster and 
therefore exhibits no enzymatic activity as an aconitase [6].  Another important difference 
between IRP1 and IRP2 is the insertion of a 73 amino acid sequence in IRP2 that contributes 
to the  iron- and oxygen-dependent modulation of protein stability and degradation [7].  
Under iron-replete conditions, IRP2 is targeted for proteasomal degradation via an iron-, 
oxygen-, and 2-oxoglutarate-dependent prolyl hydroxylase and subsequent recognition by the 
E3-ubiquitin ligase F-box and leucine-rich repeat protein 5 (FBXL5) [8].  Under iron-
deficient conditions IRP2 is stabilized by inhibition of the prolyl hydroxylase and de-
stabilization of FBXL5 [9].  
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Interestingly, the effects of iron deficiency (ID) on IRP function and activity appear 
to be tissue-specific.  For example, in the livers of ID animals, IRP1 binding activity only 
increases to about 10% of the available pool of IRP1 protein, suggesting that even under ID 
conditions ~90% of the protein exists as c-acon/holoIRP (Clarke and Eisenstein, unpublished 
data).  However, in skeletal muscle (i.e., gastrocnemius and soleus), nearly 100% of the 
available IRP1 protein pool is converted to apoIRP1 under iron-deficient conditions (Clarke 
and Eisenstein, unpublished data).  Further, the total abundance of IRP1 is decreased in 
skeletal muscle, but not liver, in response to ID.  These findings not only provide evidence of 
a tissue-specific response, but also reveal an additional mechanism (via decreased protein 
stability, enhanced turnover, repressed translation, or decreased mRNA abundance) that may 
play a role in controlling IRP1 activity.  Indeed, as described above, the primary means of 
regulating IRP1 activity is through the formation or loss of a [4Fe-4s] iron-sulfur cluster.  
Previous studies have also demonstrated significant reductions in mitochondrial enzyme 
activity, Fe-S cluster enzyme content, and the Fe-S cluster assembly cysteine desulfurase 
protein (IscS) abundance in skeletal muscle in response to dietary ID [10-12].  In fact, the 
majority of the negative health consequences resulting from iron deficiency arise from 
alterations in iron metabolism in skeletal muscle [13].  This observation has largely been 
attributed to impaired Fe-S cluster protein function that are essential for numerous biologic 
processes including maintenance of iron homeostasis, mitochondrial respiration, electron 
transfer, cellular metabolism, and gene regulation [13, 14].   
The indispensable nature of iron is also reflected by its critical role in many cellular 
processes including oxygen transport, DNA synthesis, ATP generation, and cellular 
differentiation and proliferation.  Unfortunately, ID remains a major public health concern, 
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affecting as much as 25% of the world’s population [15].  ID progresses in stages and can 
occur with and without anemia.  Anemia occurs in the final stage of ID when iron depletion 
is severe and there is an inadequate supply of iron to support erythropoiesis.  Symptoms of 
ID anemia include weakness, fatigue, reduced capacity to transport oxygen, impaired 
cognitive function in children, and a reduced ability to fight infection [16, 17]. 
In animal models, less well characterized responses to ID include alterations in lipid 
and glucose metabolism as a result of decreased oxidative capacity, leading to a shift in 
preferential fuel utilization from fat to glucose [18-20].  These animals also display signs of 
disrupted metabolic homeostasis as they exhibit hyperglycemia, hyperinsulinemia, and 
hyperlipidemia presumably as a result of alterations in insulin signaling [18, 21].  Another 
interesting finding in the investigation into the metabolic response to iron deficiency is that 
the severity of these consequences (i.e., hyperglycemia and hyperlipidemia) appears to be a 
graded response to a reduction in hemoglobin [22].  There is an inverse correlation between 
decreasing hemoglobin levels through the progression of anemia and elevated serum levels of 
lipids and glucose.  The extent to which these metabolic responses associated with ID are the 
result of a physiologic adaptation to iron deficiency, or pathologic consequences of 
insufficient iron availability remains relatively unknown.  
Regardless, a reduction in iron status is clearly associated with negative physiologic 
effects.  In addition to the consequences associated with the loss of Fe-S cluster protein 
activity, a major reason for the adverse side effects observed with ID is due to the 
requirement of iron for the biosynthesis of heme, which as the primary component of 
hemoglobin makes oxygen transport possible.  Additionally, other heme-containing proteins 
(e.g., cytochromes) have critical roles in ATP generation, lipid metabolism, and steroid 
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hormone synthesis [13, 23].  Iron in the form of heme also acts as a cofactor in regulating 
protein function.  For instance, heme binding enhances the regulatory capacity of the 
transcriptional repressor Rev-erbα, and thereby implicates iron as having potential roles as a 
key integrator of circadian and metabolic pathways [24].  Recent findings have expanded the 
physiologic roles of heme even further as a potential regulator of mRNA stability and 
degradation via the critical role it has been shown to play in microRNA (miRNA) processing 
[25, 26].   
miRNA are a class of noncoding RNA approximately 22 nucleotides (nt) long that are 
predicted to regulate as much as 60% of all protein-coding genes, and thus contribute to the 
coordination of a variety of biological processes [27, 28].  miRNA are potential candidates 
for the currently unidentified tissue-specific regulation of IRP in response to ID as they are 
often expressed in tissue-specific patterns and may affect both the spatial and temporal 
regulation of many protein-coding genes [29, 30].  In fact, the oxygen sensitive miR-210 has 
been shown to regulate the protein abundance of iron-sulfur cluster assembly proteins 
(ISCU1/2) in cultured cells, and therefore could potentially play a significant role in the 
regulation of IRP1 activity as well [31, 32].  Also, the liver-specific miR-122 has been shown 
to play a significant role in the regulation of lipid metabolism and systemic iron homeostasis 
in mice, and likely contributes to the metabolic response to ID [33, 34]. 
As mentioned above, the negative health consequences resulting from ID are 
primarily due to alterations in iron metabolism in skeletal muscle [13, 35, 36].  Interestingly, 
the liver appears to be relatively resistant to the effects of ID in terms of mitochondrial 
metabolism and heme-containing protein functions, though relatively little is known about 
the molecular mechanisms regulating iron metabolism in different tissues and how alterations 
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in iron status in different tissues affect iron homeostasis.  As mentioned above, one potential 
candidate regulatory mechanism is mediated by the iron-dependent expression of miRNA.  
Indeed, there is accumulating evidence suggesting that miRNA may also contribute to the 
coordination of mammalian iron homeostasis [37].  This evidence for the role of miRNA in 
modulating iron homeostasis is underscored by the fact that miRNA processing is, at least in 
part, a heme-dependent process [25, 26]. 
The rationale for the proposed work is that determination of the roles of miRNA in 
coordinating the molecular response to changes in iron status will provide fundamental 
insights into the understanding of how iron homeostasis is maintained and how alterations in 
iron sensing can lead to the development of disease.  Thus, our primary objectives were to 
(1) examine miRNA expression profile under iron-adequate and iron-restricted conditions in 
animals, (2) to identify differentially expressed miRNA, (3) to examine the potential targets 
of differentially expressed miRNA, and (4) to characterize the impact of miRNA expression 
on putative targets involved in iron metabolism.  The central hypothesis was that miRNA 
expression would be regulated in response to ID and that these changes would be associated 
with changes in the expression of target mRNA resulting in the homeostatic regulation of 
cellular iron metabolism.  This research has provided insight as to how miRNA contribute to 







REVIEW OF LITERATURE 
 
 
Chalybeate (iron-containing) waters in Europe were first recognized for their 
healing properties in medieval times.  Later, in the 1600s, iron fillings were steeped in 
wine, and supplemented orally to ward off chlorosis, a condition we now recognize as 
anemia [38].  This is quite remarkable as the role of iron in the development of anemia 
was not properly described until the 1930s [39, 40].  As a result of these findings, 
developed countries began fortifying flour and processed foods with iron in the 1940s in 
an attempt to stave off iron deficiency, a practice that still continues in the present day.  
Additionally, numerous pharmacological resources now exist for the treatment and 
correction of iron deficiency.  Yet, despite the tremendous expansion in our 
understanding of the etiology of iron deficiency anemia, and massive treatment and 
prevention efforts, iron deficiency remains a major public health problem.  
The persistence of iron deficiency throughout the millennia is multi-faceted.  The 
unregulated, but nominal excretion of iron by humans is insufficient to deplete body iron 
stores, and thus iron sufficiency is largely regulated at the level of intake and absorption.  
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Nutritional iron deficiency occurs when dietary iron intake or iron absorption 
does not meet physiological requirements, and can result from several factors.  For 
example, rapid growth coupled with a low iron diet can result in iron deficiency in 
children, and premenopausal women may become iron deficient due to frequent heavy 
menstrual blood loss.  In under-developed countries, blood loss as a result of parasitic 
infection can also exceed dietary iron intake, resulting in iron deficiency [17].  Other 
conditions that often result in iron deficiency include infections, tumors, inflammation, 
and genetic disorders.    
Iron deficiency is a major public health concern because a reduction in iron status 
can result in significant negative physiologic effects.  Symptoms of iron deficiency 
include weakness, fatigue, reduced work capacity, impaired cognitive function in 
children, and increased susceptibility to infection [17].  Globally, iron deficiency affects 
billions of people and its symptoms are attributed to the loss of millions of dollars, and to 
the death and disability of more than 800,000 individuals annually through increased risk 
of child and mother mortality, reduced fitness and productivity, and cognitive impairment 
[41, 42].  Thus, understanding the pathology of the manifestations of iron deficiency is of 
utmost importance, because although the causes are clear, iron deficiency persists, and 
the consequences are significant.  Outlined below is a detailed review on our current 
understanding of iron needs, metabolism, and regulation, and the exquisite molecular 
controls coordinating iron homeostasis. 
The necessity and toxicity of iron 
The maintenance of optimal iron status is critical for numerous reasons.  Too little 
iron can result in the development of anemia while too much iron is toxic and can lead to 
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tissue damage and failure.  The former is most often caused by dietary intake that is 
insufficient to meet physiologic needs, while the latter is most commonly caused by 
diseases of iron metabolism, such as hereditary iron overload.  Remarkably, the features 
of iron that are attributed to the crux of its essentiality, the ability to undergo oxidation 
and reduction, are the same properties that largely contribute to its potential for toxicity.  
In addition to its properties as a transition metal however, iron is also an essential nutrient 
because of the vital role it plays in many life preserving functions including oxygen 
transport (hemoglobin), cellular respiration (cytochromes), and DNA synthesis 
(ribonucleotide reductase). 
The daily production of hemoglobin containing red blood cells accounts for the 
majority of iron utilization in the body and represents nearly 80% of the iron demand in 
humans [43].  Each day the body produces approximately 200 billion new red blood cells, 
each of which contains millions of hemoglobin molecules, requiring some 20 mg of iron 
per day [43].  Hemoglobin is the primary oxygen transporter from the lungs to various 
tissues, and thus is essential for respiration.  It is the presence of the iron atom at the 
center of heme that makes the transport of oxygen by hemoglobin possible.  When 
insufficient iron is available for optimal hemoglobin synthesis, anemia ensues, total 
oxygen carrying capacity of the blood decreases, and the symptoms of iron deficiency 
begin to manifest [13].   
Iron, in the form of heme, also has many other biologic functions.  The presence 
of iron in heme-containing cytochromes enables the transport of electrons.  In the 
electron transport chain, cytochromes, such as cytochromes b and c, pass along single 
electrons; the transfer of which is made possible by the change in the oxidation state of 
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iron from the ferrous (Fe
2+
) to the ferric (Fe
3+
) state [44].  It is this oxidation of nutrients 
through the electron transport chain that makes their energy release to the body possible.  
Other heme-containing cytochromes, such as cytochrome P-450 are involved in oxidative 
degradation of drugs and steroid hormone synthesis [13].  Iron in the form of heme also 
acts as a cofactor in regulating protein function.  For instance, heme regulatory motifs 
have been characterized in three major circadian regulators: neuronal PAS domain 
protein 2, nuclear receptor subfamily 1, and Period 2 [23].  Recent findings have 
expanded the physiologic roles of heme even further as a potential regulator of mRNA 
stability and degradation via its critical role in microRNA processing, a function which 
will be discussed in much more detail below [25, 26].  Thus, heme can serve as an 
integrator of mammalian energy metabolism and circadian rhythm as well as a regulator 
of mRNA expression and function. 
Non-heme iron containing compounds also comprise an important group of 
proteins and enzymes essential for normal physiologic function.  Proteins containing 
iron-sulfur (Fe-S) clusters are found in virtually all living cells and within multiple 
cellular compartments including the mitochondria, cytosol, and nucleus [45].  Fe-S 
clusters in proteins act as cofactors that are essential for numerous biologic processes 
including maintenance of iron homeostasis (IRP1), mitochondrial respiration 
(mitochondrial aconitase), electron transfer (NADH), and DNA repair (Fanconi anemia 
group J and Xeroderma pimentosum group D) [14, 46].  Expression and function of Fe-S 
proteins is largely influenced by alterations in iron status, and likewise mutations in Fe-S 
cluster assembly proteins are causative of human disease. 
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Despite the essentiality for iron in critical life preserving functions, it is equally 
important to note there is also considerable potential for iron toxicity.  Because there is 
not a regulated mechanism to control iron excretion, excess iron can accumulate in body 
tissues and organs.  As mentioned above, it is the redox capability of iron which 
contributes both to its essentiality and toxicity.  In excess, this redox activity can lead to 
the generation of damaging free radicals via Fenton chemistry, which is the reaction 
between hydrogen peroxide and ferrous iron that can produce hydroxyl radicals and other 
oxidizing species capable of creating biological injury [47]. 
Indeed, iron accumulation in the brain has been linked to oxidative damage and 
neurodegeneration associated with multiple sclerosis, Friedrich’s ataxia, Parkinson’s, and 
Alzheimer’s disease [48].  Additionally, oxidative stress and damage has been implicated 
as a causative factor for several chronic diseases including cardiovascular disease and 
diabetes [49, 50].  The role of iron in the pathogenesis of these two diseases has been 
supported by epidemiological evidence indicating that elevated iron storage levels are 
associated with increased risk of coronary heart disease and insulin resistance [50, 51].  
Although an exact mechanism has yet to be elucidated, the potentially toxic 
characteristics of iron are suspected to play a critical role. 
Unlike iron deficiency, iron overload and toxicity is rarely attributed to a dietary 
imbalance, and instead is most commonly observed in individuals with genetic 
conditions.  For instance, hereditary hemochromatosis is the most common genetic iron 
overload disorder affecting approximately 1/200 individuals of northern European 
descent [52].  It is associated with mutations in the HFE gene and characterized by 
dysregulation of intestinal iron absorption and inappropriate parenchymal iron deposition 
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[53, 54].  Early symptoms of excess iron deposition include fatigue, joint pain, 
depression, impotence, and increased skin pigmentation [53].  Left untreated, patients 
with hemochromatosis accumulate iron in tissues like the liver, heart, and pancreas 
resulting in the development of cirrhosis, cardiomyopathy, and diabetes, respectively 
[53].   
Several other iron overload or hemochromatosis disorders exist that are not 
associated with mutations in the HFE gene.  For example, “juvenile or Type II 
hemochromatosis,” is associated with the same phenotypic characteristics as type I 
hemochromatosis but is due to mutations in the gene encoding hemojuvelin (HJV) also 
known as HFE2 [43, 55].  Individuals with juvenile hemochromatosis accumulate iron at 
a much faster rate and tend to experience cardiomyopathy and other endocrinopathies 
rather than severe liver disease [55].  In the absence of treatment, these patients typically 
suffer from heart failure before age thirty [53, 55].  Other types of hemochromatosis can 
result from mutations in genes encoding the iron hormone hepcidin (HAMP1), the iron 
uptake protein transferrin receptor 2 (TfR2), and the iron export protein ferroportin [43].  
The importance of each of these proteins in the regulation of mammalian iron metabolism 
is discussed in more detail below.  
Iron absorption, transport, uptake, and storage 
 The control of iron homeostasis is primarily influenced by an individual’s iron 
needs and status of body iron stores.  Because there is no regulated means for iron 
excretion, homeostasis is primarily mediated through controlling dietary absorption.  
Intestinal iron absorption is largely influenced by organismal iron status, and may range 
from 10% (for an individual with normal iron status) up to 35% (for an individual who is 
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iron deficient) [56].  Iron absorption can occur throughout the entire length of the small 
intestine, but iron is most efficiently absorbed in the duodenum [56].  Dietary iron exists 
as either heme iron (from meats) or nonheme iron (from plants).   
 Heme iron is actually much more efficiently absorbed than nonheme iron, but the 
mechanisms by which it is absorbed remain poorly understood.  Although heme 
transporters have been described, their roles in intestinal iron absorption are not fully 
agreed upon, and appear quite nominal [57-59].  However, it is generally believed that 
most dietary heme iron is internalized then disassembled by heme oxygenase to enter a 
common pathway with dietary nonheme iron.  Most dietary nonheme iron is found in the 
ferric form, but must be reduced to ferrous iron either chemically or through the action of 
the iron-regulated brush border enzyme duodenal cytochrome reductase (Dcytb or 
Cybrd1) before being transported across the luminal membrane of the enterocyte by 
divalent metal transporter-1 (DMT1) [60].  The importance of Cybrd1 in non-heme iron 
absorption remains enigmatic however due to the finding that the loss of Cybrd1 has no 
effect body iron stores, indicating that alternative pathways for reduction of dietary iron 
likely exist in the intestine [61].   
Regardless of form, once in the enterocyte, iron has three fates: (1) 
storage/excretion, (2) utilization, or (3) transport to other tissues.  Iron that is not 
transported out of the enterocyte can be incorporated into the iron storage protein ferritin 
for short-term storage [62].  If iron is not needed, it can be “excreted” with the short-lived 
mucosal cells that are sloughed off every 2-3 days [63].  If needed however, iron can be 
released from ferritin for utilization by the intestinal cells as a cofactor for enzymes, or 
transported out for utilization by other tissues.  Iron is transported out of the enterocyte 
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across the basolateral membrane by the iron export protein ferroportin (Fpn) [43].  
Mutations in hemochromatosis gene product HFE result in an increase in the expression 
of DMT1 and Fpn in the duodenum contributing to the inappropriate increase in intestinal 
iron absorption and export in individuals with hereditary hemochromatosis [64]. 
 Following export across the basolateral membrane, ferrous iron is oxidized by the 
multi-copper oxidase hephaestin (Heph) prior to being loaded onto the iron transport 
protein transferrin (Tf) [65].  Tf, a glycoprotein, binds a maximum of two iron atoms and 
serves as the primary means for interorgan transport [66].  Tf plays a critical role in iron 
transport as it has the capacity to reversibly bind iron.  This is important because at 
physiological (neutral) pH, iron is insoluble in its free state and is capable of generating 
free radicals.  However at a neutral pH, Tf binds to iron with high affinity making it 
safely available for transport to other body tissues such as the liver, muscles, and bone 
marrow [65].   
Iron uptake in these tissues occurs through clathrin-dependent endocytosis of 
transferrin via interaction with transferrin receptors (TfR) 1 and 2 [62, 65].  Both TfR1 
and 2 are capable of complexing with Tf for the internalization of iron, but while TfR1 is 
ubiquitously expressed, TfR 2 expression is limited to hepatocytes and erythroid cells 
[67].  TfR1 also has a much higher affinity for Tf than Tfr2, and as such represents the 
primary means of iron uptake in most cells [62, 67].  However, at least nine mutations 
have been characterized in TfR2 that lead to a severe early-onset form of hereditary 
hemochromatosis, and thus TfR2 is also a critical factor in the control of iron 
homeostasis [68].  Once bound, the Tf/TfR complex is endocytosed, where the acidic pH 
of the endosome results in the release of iron, and Tf and TfR are recycled back to the 
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cell surface where they disassociate upon encountering the nearly neutral pH [69].  The 
released iron is then reduced by Steap metalloreductases before being pumped into the 
cytoplasm, most likely by DMT1 [62, 69].  Once in the cytoplasm, iron is used by the cell 
(i.e., in the production of iron-containing proteins), exported out of the cell via 
ferroportin, or stored in the primary cellular iron storage protein, ferritin.  
Ferritin is a cytosolic protein involved in iron storage and detoxification in 
microbial, plant, and animal species [62, 66].  In mammals, ferritin molecules are present 
as heteropolymers with 24 subunits of two types, H-subunits (heavy or heart) and L-
subunits (light or liver) [70].  Both ferritin types are ubiquitously expressed, but their 
expression ratios vary greatly depending on the tissue and cell type, with H-ferritins 
predominating in the heart and brain, and L-ferritins being more prevalent in the liver and 
spleen [71].  H-subunits exhibit ferroxidase activity that promotes the loading of iron into 
storage, whereas L-subunits are more efficient at promoting mineralization of nuclei [72].  
Homopolymers of H-type ferritin are also found in the mitochondria where they provide 
the same protective and storage functions as their cytosolic counterparts [71].  The 
delivery of non-utilized iron from the cytosolic pool to ferritin remains unclear, but the 
iron chaperone protein poly (C)-binding protein 1 (PCBP1) does facilitate the iron 
loading of ferritin in vitro and in cultured cells [71].  However, the contribution of 
PCBP1 to the loading of ferritin and the maintenance of iron homeostasis in vivo remains 
to be elucidated.  Under physiologic conditions it is generally thought that iron release 
occurs with lysosomal or proteosomal degradation of ferritin, but it remains unclear how 
iron is then made available for use or transport [71].   
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The liver is a primary site of iron storage, accounting for approximately 60% of 
the ferritin in the body, but of particular significance is the remaining 40% of ferritin 
found in the cells of the reticuloendothelial system (RES) [73].  Iron is recycled by 
specialized macrophages within the RES that phagocytose senescent or damaged red 
blood cells and remove them from circulation [74].  This is important because while the 
1-2 mg of iron absorbed each day is sufficient to counter obligatory iron losses (i.e., 
bleeding and sloughing off of mucosal and skin cells) of around 1 mg per day, daily 
erythrocyte production (200 billion red blood cells per day) requires 20-24 mg of iron for 
hemoglobin synthesis [43].  Thus, while absorption of dietary iron is important to satisfy 
daily iron losses, it is the body’s mechanism of conserving and recycling iron that ensures 
proper iron stores.   
 Within the macrophages, red blood cells are lysed and hemoglobin is degraded by 
heme oxygenase which catalyzes the liberation of iron from heme [43].  Macrophages 
can then either store the iron derived from hemoglobin in ferritin or release iron through 
the iron export protein Fpn with the aid of soluble multi-copper oxidase cerruloplasmin 
[74].  The majority of iron entering the plasma for distribution or redistribution by 
transferrin is derived from the RES, sites of hemoglobin destruction, and/or ferritin and 
hemoglobin degradation [73].  Thus, cells of the RES and the signaling molecules that 
regulate their function play a critical role in maintaining whole-body iron homeostasis.   
Systemic iron homeostasis 
The adult human body contains iron in two major pools: 1) functional iron in 
hemoglobin, myoglobin, and enzymes and 2) storage iron in ferritin and transferrin.  The 
majority of iron is found in the functional pool, with only about 20% remaining as 
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storage iron (found primarily in hepatocytes and the macrophages of the RES) [73].  
Because of iron’s essential, yet potentially toxic nature, iron homeostasis must be 
maintained at both systemic and cellular levels, and movement between these two pools 
must be tightly regulated.  As there is no regulated mechanism for iron excretion, 
systemic iron balance is tightly maintained through the regulation of absorption from the 
intestine.  Four situations lead to measurable changes in iron absorption: abnormal iron 
availability (overload or deficiency), accelerated erythropoiesis, hypoxia, and 
inflammation. [75, 76].  In this manner, iron absorption and plasma availability is 
decreased in response to iron overload and inflammation, and increased in response to an 
inadequate iron status, enhanced erythropoiesis, and hypoxia [43, 76].   
 Much enthusiasm was generated when the small peptide hormone hepcidin, 
initially thought to function as an antimicrobial agent, was shown to be a major regulator 
of both intestinal iron absorption and iron recycling within the RES [1, 2].  Hepcidin is 
now recognized as a key iron regulatory hormone responsible for coordinating iron 
absorption with existing iron stores to meet systemic iron needs.  Hepcidin, which is 
secreted by the liver, regulates systemic iron metabolism by promoting the 
internalization, ubiquitination, and lysosomal degradation of the iron export protein Fpn 
in both enterocytes and the macrophages of the RES [1, 77].  Thus, when iron stores are 
elevated, hepatic hepcidin expression and secretion are increased and iron absorption and 
release from stores is diminished.  Conversely, when iron stores are low, hepcidin 
expression is decreased and intestinal iron absorption and iron release from the RES is 
enhanced.  Mutations in HAMP1, the gene encoding hepcidin, are associated with the 
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development of a severe type of juvenile hemochromatosis and illustrate the central role 
this peptide hormone plays in the regulation of systemic iron homeostasis [1, 2]. 
Regulation of hepatic hepcidin expression occurs at the transcriptional level.  
Hepcidin expression is decreased in response to situations such as anemia and hypoxia, 
but is increased in response to inflammation [76].  Key molecules in the regulation of 
hepcidin expression include the hemochromatosis gene product, HFE, the bone 
morphogenetic protein (BMP) co-receptor, hemojuvelin (HJV), and the iron sensor TfR2.  
One means of hepcidin regulation is through the binding of HFE with the iron uptake 
proteins TfR1 and TfR2.  In this manner HFE has been suggested to act as a bimodal 
switch between these two iron sensors because high concentrations of transferrin bound 
iron displace HFE from TfR1 and promote its interaction with TfR2 [78].  The HFE-
TfR2 complex then binds HJV and activates hepcidin transcription via BMP/SMAD 
signaling [78, 79].   
 While HFE and TfR2 interaction can contribute to hepcidin activation, hepcidin 
transcription is predominantly controlled through iron activated BMP6 interaction with 
the BMP co-receptor HJV.  To date, how BMP6 mRNA expression is modulated in 
response to increasing and decreasing iron levels remains to be determined  [62].  Once 
bound, the BMP-HJV complex activates hepcidin transcription by interacting with type I 
and II BMP receptors at the plasma membrane, which induces phosphorylation of 
receptor-activated SMAD (R-SMAD) proteins that can then dimerize with SMAD4 [80].  
The R-SMAD/SMAD4 heterodimer can then translocate to the nucleus and activate 
transcription of the HAMP1 gene [77, 80].  Hepcidin regulation in response to 
erythropoietic signals is also influenced by BMP-SMAD signaling, which is inhibited by 
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the release of erythroid precursors [62].  Inflammatory stimuli such as interleukin 6 can 
also induce HAMP1 transcription through activation of STAT3 (which also requires the 
presence of SMAD4) and the subsequent binding of STAT3 to a regulatory element in 
the HAMP1 promoter [81]. 
Modulation of hepcidin expression in response to situations such as anemia, 
hypoxia, and inflammation suggest hepcidin is a key regulator of iron homeostasis under 
various pathophysiological conditions [76].  This evidence has been further supported by 
work demonstrating that complete lack of hepcidin in mice results in iron overload, while 
animals overexpressing hepcidin experience decreased body iron levels and severe 
anemia [82, 83].  Moreover, mutations in hepcidin regulatory molecules such as HFE, 
HJV, and TfR2 in humans result in iron overload due to the absence of hepcidin 
expression [84].  Similarly, mutations in the transmembrane protein matriptase 2 
(TMPRSS6), which leads to inappropriately elevated hepcidin transcription, are the 
genetic basis for iron-refractory iron deficiency anemia [85].  Thus, an effective means of 
hepcidin administration in response to iron overload or a means to counteract the 
overexpression of hepcidin seen in genetic and inflammatory diseases could have 
momentous pharmacological value.   
As described above hepcidin’s primary mode of action for the maintenance of 
systemic iron homeostasis is through its posttranslational regulation of the iron exporter 
Fpn.  Also mentioned was the fact that hepcidin gene expression is influenced by hypoxic 
stimuli, (which can enhance erythropoiesis), and alterations in iron levels (signaled by 
TfR).  It is of note then that these three critical components of systemic iron homeostasis: 
cellular iron export (Fpn), iron utilization (erythropoiesis), and iron uptake (TfR), are 
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subject to tight regulation at cellular level as well.  However, while the targets of 
systemic and cellular iron coordination overlap, the machinery controlling the cellular 
iron homeostasis is quite different. 
Cellular iron homeostasis 
 The coordination of iron uptake, storage, and utilization is critical in maintaining 
optimal levels or iron and the appropriate distribution of the intracellular iron pool.  A 
number of proteins intimately involved in the maintenance of cellular iron homeostasis 
are regulated post-transcriptionally by the so-called “global regulators” of iron 
metabolism, Iron Regulatory Proteins (IRP).  It is through the actions of the two iron 
regulatory proteins, IRP1 and IRP2, which both act to “sense” the intracellular iron 
status, that total body iron homeostasis is tightly controlled.  IRP regulate iron 
metabolism through high-affinity binding to highly conserved stem-loop structures of 
CAGUGX hexanucleotide loop sequence in mRNA termed Iron Responsive Elements 
(IRE) [4, 86].  These conserved stem-loop structures are located in either the 5’ 
Untranslated Regions (UTR) or 3’UTR of mRNA encoding proteins of iron metabolism, 
and alter protein translation or mRNA stability, respectively [4].   
 Both IRP1 and IRP2 function as high-affinity cytosolic RNA binding proteins that 
are regulated in an iron-dependent manner.  IRP1 is a bifunctional protein exhibiting 
either high affinity RNA binding protein activity or enzymatic activity by functioning as 
the cytosolic isoform of the TCA cycle enzyme aconitase (c-acon) [3].  The activity (or 
function) of the protein is largely dependent on the presence or absence of the iron-sulfur 
Fe-S cluster [3, 66].  Under iron replete conditions, the presence of a [4Fe-4S] iron-sulfur 
cluster confers enzymatic (aconitase) activity and inhibits high-affinity RNA binding 
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activity [87].  Conversely, under iron deficient conditions, the Fe-S cluster is 
“disassembled” resulting in the generation of high-affinity RNA binding activity (IRP1) 
[5].   
In contrast to IRP1, IRP2 does not contain a [4Fe-4S] iron-sulfur cluster and lacks 
aconitase activity functioning only as an RNA binding protein.  Rather than being 
regulated through the assembly or disassembly of an Fe-S cluster, IRP2 is regulated 
primarily through iron- and oxygen-dependent modulation of protein stability and 
degradation [6].  Aside from the lack of an Fe-S cluster, IRP2 also contains an additional 
73 amino acid sequence that is necessary for its iron-dependent regulation and 
degradation [4].  Under iron-replete conditions, IRP2 is targeted for proteasomal 
degradation via an iron- and oxygen-dependent prolyl hyrodroxylase and subsequent 
recognition by the E3-ubiquitin ligase F-box and leucine-rich repeat protein 5 (FBXL5) 
[8, 88].  Under iron-deficient conditions IRP2 is stabilized by inhibition of the prolyl 
hydroxylase [3].   
Various extracellular stimuli are capable of influencing IRP1/c-acon and IRP2 
independent of cellular iron status.  For example IRP1 activity is modulated in response 
to oxidative stress due to modifications of the [4Fe-4S] iron-sulfur cluster.  Hydrogen 
peroxide, nitric oxide, and peroxynitrite are the most well-characterized cluster 
perturbants.  They promote the loss or disassembly of the [4Fe-4S] iron-sulfur cluster 
generating the RNA binding form of the protein [4, 89].  Although interconversion of 
IRP1/c-acon via assembly and disassembly of the Fe-S cluster is thought to be the 
primary mechanism through which the protein’s activity is regulated, IRP1 activity can 
also be regulated independently of iron by other means including oxidative stress and 
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post-translational modification [89, 90].  IRP1 is regulated by protein kinase C (PCK)-
dependent phosphorylation at two PKC phosphorylation sites, S711 and S138 resulting in 
decreased aconitase activity and decreased Fe-S stability, respectively [91, 92].  IRP2 can 
also be regulated by phosphorylation [4].  Interestingly, phosphorylation of IRP2 was 
shown to increase RNA binding activity through the activation of a latent pool of IRP2 
rather than an increase in protein synthesis [93].  Thus, IRP2 appears to be able to switch 
from a high-affinity phosphorylated RNA binding protein to a low-affinity 
dephosphorylated form through the regulation of phosphatases and protein kinases [4, 
93]. 
Despite the multitude of differences in the regulation of IRP1 and IRP2, both 
exhibit similar genetic regulatory functions as central regulators of iron metabolism, 
regulating proteins involved in the uptake (DMT1), transport (TfR1), storage (ferritin), 
and utilization (erythroid aminolevulinic acid synthase) of iron.  When cells are iron 
deficient, both IRP function as high-affinity RNA binding proteins and repress the 
translation of mRNAs containing IRE in their 5’UTR (i.e., ferritin) and increase the 
stability of mRNAs containing IRE in their 3’UTR (i.e., TfR1) [3].  Under iron replete 
conditions, IRP lose their high-affinity RNA binding capacity and fail to bind IRE 
thereby de-repressing ferritin synthesis and decreasing TfR mRNA stability [3]. 
In addition to regulating the expression of proteins directly involved in the 
maintenance of iron homeostasis, IRP also regulate mRNA encoding proteins involved in 
energy metabolism and oxygen sensing.  For instance IRE have also been identified in 
the 5’UTR of mRNA encoding mitochondrial aconitase (m-acon) and the iron-protein 
subunit of succinate dehydrogenase (SDH - in Drosophila only), two TCA cycle 
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enzymes[4, 94].  The regulation of m-acon and SDH via the IRE/IRP system provides a 
direct link between iron and energy metabolism and is thought to play an important role 
in fuel utilization during iron deficiency [94, 95].  The discovery of an IRE in the 5’UTR 
of the hypoxic transcription factor, hypoxia inducible-2α mRNA provided new insight 
into the physiologic adaptation to iron deficiency [96].  It was well established for some 
time that the hypoxic down-regulation of hepcidin to increase iron availability for 
stimulation of red blood cell production served to meet physiological needs by increasing 
oxygen transport [76, 97, 98].  However, under iron limiting conditions, stimulation of 
erythropoiesis could lead to the production of hypochromic microcytic red blood cells 
due to impaired hemoglobin production and further deplete already low iron stores.  The 
IRP-mediated functional repression of HIF-2α protein expression in response to iron 
deficiency shed new light onto how the rate of red blood cell production, and thus iron 
utilization, is adjusted based on iron availability [99, 100].   
Interestingly, the effects of iron deficiency on IRP function and activity have been 
shown to be tissue-dependent.  While the liver appears to be relatively resistance to 
changes in iron status, the skeletal muscle is severely affected [10, 13].  For instance, 
spontaneous binding activity of IRP1 in the livers of iron-deficient animals only increases 
to about 10% of the available pool of protein (Clarke, unpublished data).  However, in 
skeletal muscle, nearly 100% of the available IRP1 protein pool is converted to the active 
IRE binding form under iron-deficient conditions (Clarke, unpublished data).  As 
described above, the functional role of IRP1 is largely dependent on the presence of a 
[4Fe-4s] cluster.  Intriguingly, the protein abundance of the mitochondrial cysteine 
desulfurase iron-sulfur cluster S (IscS) is negatively impacted in the skeletal muscle, but 
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not livers of rats fed an iron deficient diet [10].  Therefore, it is tempting to postulate the 
observed tissue-specific effects on IRP1 RNA binding activity are the result of iron-
dependent effects on the Fe-S cluster machinery 
Iron-sulfur cluster proteins 
Fe-S clusters in proteins, such as IRP1, act as cofactors that are essential for 
numerous biologic processes including maintenance of iron homeostasis, mitochondrial 
respiration, electron transfer, metabolism, and many other regulatory processes [14].  
Proteins containing Fe-S clusters are found in virtually all organisms, and within multiple 
cellular compartments including the mitochondria, cytosol, and nucleus.  The synthesis 
and assembly of Fe-S clusters is a complex and highly regulated process involving the 
delivery of iron and sulfide to specific apoproteins located within the subcellular 
compartments [14].  A spectrum of human diseases associated with a dysregulation in 
cellular iron metabolism have been attributed to mutations in genes involved in Fe-S 
cluster biogenesis, such as the iron-sulfur assembly proteins Iscu1/2 [45, 46].  Given the 
importance of Fe-S proteins in the regulation of iron homeostasis (i.e., IRP1) and energy 
production (i.e., m-acon), which is reduced in iron deficiency, it is of interest to identify 
and elucidate regulatory factors involved in the formation and maintenance of Fe-S 
clusters, particularly in response to iron deficiency. 
In mammals, more than ten proteins have been identified as having critical roles 
in the maturation of mitochondrial Fe-S proteins, although several more candidate 
proteins are predicted to be involved [45].  A key initial step in Fe-S protein biogenesis is 
the generation of sulfur by the cysteine desulfurase, nitrogen fixation homolog (Nfs1 or 
IscS) and its obligatory partner Isd11 [45].  The sulfane sulfur generated by Nfs1/Isd11 
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then has to be reduced, most likely by ferredoxin reductase and ferrodoxin, before being 
assembled onto the iron sulfur scaffold homolog, Iscu [46].  The movement of iron within 
the cell is one of the least understood problems in iron biology, so another initial, but less 
well defined step in Fe-S biogenesis is the transfer of iron onto the scaffold protein.  
However, two mitochondrial importers have been identified, mitoferrin 1 (Mfrn1 or 
Slc25a37) and mitoferrin 2 (Slc25a28), that can mediate the transport of iron in its 
reduced form into the mitochondrial matrix [45, 62].  The assembly of iron onto the 
scaffold protein is then believed to be mediated by the iron-binding protein frataxin by 
undergoing an iron-stimulated interaction with Nfs1/Isd11 [14].  Following assembly of a 
transient Fe-S cluster on Iscu, its transfer and assembly into apoproteins is facilitated by a 
mitochondrial monothiol glutaredoxin (GLRX5) and through coordination with specific 
amino acid ligands for formation of the final protein product [14]. 
As mentioned above, Fe-S cluster proteins are utilized in multiple subcellular 
compartments, but whether they all originate from the mitochondria is still up for debate.  
Nonetheless, and even though the molecular mechanisms remain poorly defined, 
maturation of both cytosolic and nuclear Fe-S proteins is absolutely dependent upon the 
function of the mitochondrial Fe-S assembly machinery [46, 62].  This is further 
evidenced by the requirement for the export of a yet unknown compound by the 
mitochondrial transporter ABCB7 for the maturation of cytosolic, but not mitochondrial 
Fe-S proteins [101, 102].  Thus, because mitochondria are the primary site of Fe-S cluster 
biogenesis (and heme synthesis), mitochondria represent a major subcellular site for iron 
utilization.  It is important then that mitochondrial iron homeostasis be tightly regulated 
in an effort to preserve proper mitochondrial function.  Recent work has shown that IRP 
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are critical for securing mitochondrial iron supplies and protecting against detrimental 
iron deficiency [103].  Interestingly, proper functioning of the mitochondrial Fe-S cluster 
assembly machinery itself is also required for mitochondrial iron homeostasis as 
depletion of Fe-S cluster biogenesis proteins results in marked iron accumulation [46].  
Furthermore, mitochondrial iron overload is a feature of many human Fe-S cluster 
assembly disorders [46]. 
In addition to contributing to mitochondrial iron homeostasis, Fe-S cluster 
containing proteins have numerous other regulatory capacities.  This is strongly 
evidenced by a number of diseases that are attributable to abnormal Fe-S cluster 
biogenesis, such as Friedreich’s ataxia and X-linked sideroblastic anemia [45, 46].  
However, it is of note that Fe-S proteins can also be affected by non-pathologic means as 
well.  For instance, dietary iron deficiency can have a significant negative impact on Fe-S 
cluster protein abundance and function.  Intriguingly however, Fe-S cluster protein 
function in skeletal muscle is strikingly more affected by iron deficiency that in other 
tissues [10, 13].  As mentioned above, total IRP1 RNA binding activity is decreased in 
skeletal muscle in response to iron deficiency, but unaffected in the liver (Clarke, 
unpublished data).  Similarly, c-acon activity is unchanged in the liver, but significantly 
decreased in the muscles of iron deficient rats [10, 104].  Previous studies have also 
demonstrated significant reductions in mitochondrial enzyme activity, Fe-S enzyme 
content, and IscS protein abundance in skeletal muscle in response to dietary iron 
deficiency [10-12].  Currently, the mechanisms underlying the tissue-specific responses 
to iron deficiency remain unknown, but the recent discovery of a new class of small 
regulatory molecules called microRNA (miRNA) has begun to receive a lot of attention 
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as miRNA because of their tissue-specific expression patterns and anticipated 
participation in nearly every biological process within the cell. 
A brief introduction to microRNA 
 The first miRNA, lin-4, was discovered in 1993, and was identified as being 
critically important for developmental timing in Caernorhabditis elegans, although at the 
time it was largely considered an anomaly in worm genetics [105].  The next miRNA 
discovered, let-7, was not identified until 2000 [106].  Intriguingly, the miRNA let-7, also 
discovered in C. elegans, was found to be highly conserved among all animals [107].  
Shortly thereafter, in 2001, several additional miRNA were discovered in Drosophila 
melanogaster and in the human HeLa cell line [108, 109].  To date (June 2013), 21,264 
precursor miRNA expressing 25,141 mature miRNA have been annotated in 193 species 
and logged in the latest (release 19) miRBase database repository [110].  The distinction 
between precursor and mature miRNA is discussed below.  With thousands of miRNA in 
numerous species being identified in a relatively short period of time, it was necessary to 
establish criteria to be used in annotating each newly discovered miRNA [111, 112].  
Each experimentally validated novel miRNA is designated with a unique name following 
these rules prior to publication.  Exceptions have been made for the miRNA let-7 and lin-
4. whose names have been retained for historical reasons.   
 First, miRNA are labeled numerically, and in sequential order with the prefix 
“mir” followed by a dash, with an un-capitalized “mir-” generally referring to the 
precursor miRNA, while a capitalized “miR-” generally denotes the mature form.  For 
instance, if the last annotated human precursor miRNA was mir-6724, the next novel 
published miRNA precursor will be numbered miR-6725.  For further clarification, the 
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names are also preceded by 3 letters signifying the species of origin, such as “hsa-” for 
Homo sapiens, “mmu-” for Mus musculus, or “dme-” Drosophila melanogaster.   
Additionally, miRNA with nearly identical structure and sequencing, barring one 
or two nucleotides, are annotated with a lower case letter such that relationships among 
miRNA can be inferred (e.g., miR-181a is closely related to miR-181b) [112].  Numbered 
suffixes, however, designate distinct precursor and genomic loci that express 100% 
identical mature miRNA [112].  For example, the designation of hsa-mir-6725-1 and hsa-
mir-6725-2 would indicate that while these two precursor miRNA may be located in 
different regions of the genome, both are processed into identical mature miRNA, hsa-
miR-6725.  miRNA which originate from the same precursor are often referred to as a 
miRNA:miRNA* (or miRNA-star) duplex [113].  With this star/non-star nomenclature, 
the non-star strand of the duplex represents the predominant functional “guide” strand, 
and the star strand represents the less abundant and more rapidly turning over 
“passenger” strand.  However, when available sequencing data is not sufficient to 
designated the predominant strand, a naming convention that identifies the miRNA strand 
location on the 5’- or 3’-arm of the precursor miRNA is used (e.g., hsa-miR-6725-5p and 
hsa-6725-3p) [113]. 
microRNA biogenesis and processing 
The majority of miRNA are derived from exons or introns of non-coding RNA, 
but approximately one-third are located in the introns of mRNA encoding genes [114].  
About half of mammalian miRNA loci are located in close proximity to other miRNA on 
the genome [114, 115].  These so-called “clustered” miRNA are likely transcribed from 
the same polycistronic transcription unit, and can work in tandem to regulate a cohort of 
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related mRNA targets [115].  Mammalian miRNA are transcribed by RNA polymerase II 
as long primary miRNA (pri-miRNA) transcripts that contain at least one hairpin 
structure consisting of a double-stranded stem and a terminal loop, and may be several 
kilobases in length [116].  In the nucleus, the pri-miRNA is cleaved at the stem of the 
hairpin structure by the microprocessor core complex composed of the RNase II-type 
protein Drosha and its cofactor known as DiGeorge syndrome critical region gene 8 
(DGCR8) [116, 117].  The product of this processing is an ~70 nucleotide (nt) long 
precursor miRNA (pre-miRNA) that is then exported out of the nucleus into the 
cytoplasm by the nuclear export factor exportin 5 (Exp5) through recognition of a short 
3’-overhang [117].  Upon entry into the cytoplasm, the RNase III-like enzyme Dicer 
catalyzes the second processing step of “dicing” the pre-miRNA to produce an ~22 nt 
long miRNA duplex [117, 118]. 
 Following cleavage by Dicer, the miRNA duplex is loaded onto an Argonaute 
(Ago) protein, which is a highly specialized small-RNA-binding protein and a critical 
component of RNA-silencing pathways [119].  Following loading onto an Ago protein, 
one of the two strands (generally the guide strand) is assembled into the RNA-induced 
silencing complex (RISC) to facilitate RNA silencing [120].  The loaded RISC is then 
competent to interact with recognition sites known as seed sequences typically located in 
the 3’UTR of target mRNA, though examples exist where the seed sequence is located in 
the 5’UTR or even within the open-reading frame of target mRNA [121, 122].  Upon 
binding to a target sequence, the RISC functions to silence the target mRNA via mRNA 
degradation or translational repression [116, 118].  The unloaded strand, often referred to 
as the passenger or miRNA* strand, was initially thought to be removed from the RISC 
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and degraded, but recent work indicates that these so-called miRNA* strands also have 
important functional regulatory roles [123, 124].  Figure 1 represents an overview of 























Figure 1.  Overview of mammalian miRNA biogenesis and function.  The primary 
(pri-) miRNA transcripts that can adopt hairpin-like structures are transcribed from 
miRNA loci.  Pri-miRNA transcripts from miRNA genes are processed to 60-80 nt pre-
miRNA transcripts by a complex containing Drosha and DGCR8 in the nucleus.  
Alternatively, pre-miRNA may be derived from intronic regions of protein-coding genes 
in a Drosha/DGCR8 independent process requiring both the splicesome and a 
debranching enzyme known as the lariat debranching enzyme.  Both the canonical 
Drosha-dependent processing and intronic processing pathways generate a pre-miRNA 
with a hairpin-like structure that is then exported out of the nucleus into the cytoplasm 
through Exportin 5 (Exp5).  Along with Argonaute (Ago) proteins, Dicer processes the 
pre-miRNA transcript into a mature miRNA duplex.  The strand in the duplex with the 
least thermodynamically stable 5’ end (guide strand) is retained by an Ago protein in 
mammals.  The passenger strand (miRNA
*
) is generally released and degraded. Upon 
target recognition by the RNA-induced silencing complex (RISC) based on the seed 
region complementarity with the target mRNA, the target mRNA undergoes translational 
repression. From:  Clarke, Stephen L., McKale R. Davis, and Ramanjulu Sunkar. 
"Biogenesis of Mammalian miRNA." MicroRNAs as Tools in Biopharmaceutical 








Interestingly, iron appears to play a critical role in miRNA processing via its 
physiological role as the functional component in heme.  This potential role for iron to 
participate in miRNA biogenesis was first demonstrated when DGCR8 was identified as 
a heme-binding protein [26].  Additional studies demonstrated that heme-free DGCR8 
was less active than heme-bound DGCR8 and suggests that an impaired ability to 
synthesize heme as a result of inadequate iron could decrease pri-miRNA processing 
[26].  In addition to heme availability, the oxidation state of iron in heme affects heme-
mediated regulation of DGCR8 [25].  The reduction of ferric heme to the ferrous heme 
abolishes DGCR8 pri-miRNA processing activity thereby affecting the rate and 
efficiency of pri-miRNA processing [25].  Recent work has now provided evidence that 
iron also regulates the processing of pre-miRNA via the iron-dependent regulation of 
Dicer activity through its association with poly(C)-binding protein 2 (Pcbp2) [125].  
Pcbp2 association with Dicer appears to promote cytosolic processing of pre-miRNA 
precursors [125].  The effect of Pcbp2 on pre-miRNA processing was enhanced with the 
removal of cytosolic iron, but not heme-iron, via the use of iron chelators [125].  Figure 










                          
Figure 2. Relationship between cellular iron and miRNA processing.  Following their 
transcription, primary miRNA (pri-miRNA) are cleaved at the stem of the hairpin 
structure by the RNase II-type protein Drosha and its cofactor DGCR8, a heme-binding 
protein.  Heme-free DGCR8 is less active than heme-bound DGCR8 suggesting that 
cellular iron status may affect the rate and efficiency of pri-miRNA processing.  The 
product of Drosha/DGCR8 processing is a ~70 nt long precursor miRNA (pre-miRNA) 
that is exported out of the nucleus into the cytoplasm by the nuclear export factor 
exportin 5 (Exp5) through the recognition of a short 3’-overhang on the pre-miRNA.  
Upon entry into the cytoplasm, the RNase III-like enzyme Dicer catalyzes the second 
processing step of “dicing” the pre-miRNA to produce a ~22 nt long miRNA duplex.  
Preliminary evidence suggests that iron also regulates the processing of pre-miRNA via 
the iron-dependent regulation of Dicer activity through its association with poly(C)-
binding protein 2 (PCBP2), wherein the removal of cytosolic iron, but not heme-iron, 
enhances pre-miRNA processing.  Following cleavage by Dicer, the miRNA duplex is 










miRNA are now recognized as the largest subclass of non-coding RNA and are 
predicted to regulate anywhere from 30% to as much as 60% of all protein-coding genes 
[27].  Indeed, the importance of miRNA has been confirmed in various cellular processes 
including cell fate determination, development, proliferation, and apoptosis, and miRNA 
are now thought to participate in nearly every biological aspect within the cell [116].  
Underscoring their importance in the maintenance of proper cell function is the fact that 
misregulation of miRNA has been implicated in the pathogenesis of many human 
diseases such as cancer and metabolic disorders [126, 127].  miRNA regulate gene 
expression by promoting mRNA degradation, inhibiting translation, or both [118].  Under 
normal physiologic conditions, miRNA act as rheostat-like regulators that serve to fine 
tune gene expression, whereas as under pathologic conditions such as stress or disease 
they tend to display a much more pronounced function. 
 Since their discovery in 1993, remarkable progress has been made in our 
understanding of miRNA biogenesis, processing, and function.  However, the details 
surrounding the mechanisms by which miRNA confer their function remain somewhat 
unclear.  In order to understand the function of a miRNA, it is first necessary to identify 
the genes that it regulates.  Unfortunately, identification of miRNA targets is a rather 
arduous task for several reasons.  Foremost, the rules of targeting are not completely 
understood [128].  Also, target identification in mammals is quite challenging because 
miRNA bind to their target mRNA with only partial complementarity over a very short 
sequence, and suppression of a target gene is often quite small [129-131].  Furthermore, 
an individual miRNA can potentially regulate hundreds of genes, and ~60% of mRNA 
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have predicted binding sites for one or multiple miRNA.  Thus, identification of miRNA 
gene targets is one of the most tedious aspects of miRNA research. 
 Several miRNA target features are important in determining miRNA:mRNA 
interaction and miRNA function.  The most important feature for miRNA target 
recognition is Watson-Crick pairing of nucleotides 2-8 from the 5’ end of the miRNA, 
known as the “seed” sequence with corresponding sites in target mRNA, referred to as 
“seed sites” [129, 131].  A “stringent” seed site has perfect Watson-Crick pairing of all 8 
nucleotides.  Bulges and mismatches, or “moderate” seed matching are also functional 
because RISC can tolerate small mismatches, or G:U wobble pairing, within the seed 
region [129].  Relative hierarchical efficacies of these seed matches are as follows: 
stringent seed > moderate stringent seed > bulge > G:U wobble [129].  Multiple seed 
sites within the target mRNA are also more efficient than single sites, and tend to exhibit 
additive effects [130].  Other features to consider when attempting to identify miRNA 
targets are site location and site accessibility.  Although functional and efficacious 
miRNA sites have been identified within the coding sequence (CDS) and 5’UTR regions, 
miRNA sites tend to be preferentially located in the 3’UTR [121, 122, 129].  This is 
likely because RISC competes with other protein complexes, such as ribosomes and 
translation initiation complexes located in the CDS and 5’UTR, respectively, making the 
3’UTR more accessible for binding [129].  Secondary structure of mRNA can also 
interfere with miRNA:mRNA interaction, and so minimum free energy can also be used 
to estimate site accessibility, but from a practical standpoint, the amount of A:Us 
surrounding the site can be an equally useful approach [129]. 
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 Once a miRNA target site has been identified, functional assays examining the 
effects of the miRNA on target gene expression is the next step in validating a bona fide 
miRNA target.  The most common approach is to clone the region of the mRNA believed 
to be targeted into a luciferase reporter [131].  This reporter construct can then be co-
transfected with a mimic or inhibitor of the miRNA of interest, and functionality can be 
assessed by either a decrease or increase in luciferase activity, respectively.  Examination 
of miRNA regulation of a target mRNA in vivo is somewhat more difficult because under 
physiologic conditions miRNA only elicit modest reductions in target gene expression 
[131].  Furthermore, it was initially thought that miRNA only repressed target translation 
in mammals, making high-throughput approaches for assessing miRNA targets quite 
difficult [118].  However, it is now recognized that miRNA can induce mRNA 
degradation, and that this is likely the primary means of target gene regulation in 
mammals [118, 132].  These findings are quite exciting because of the enhanced 
sensitivity and high-throughput capabilities of whole-transcriptome analyses techniques. 
 Even now, while we are still making vast attempts to enhance our understanding 
of how miRNA target regulation works, recent developments have added a new twist in 
the miRNA:mRNA relationship.  It is now recognized that targets can actually 
reciprocally regulate miRNA stability and miRNA function [128].  Curiously, target-
sequence interactions can both enhance miRNA stability and stimulate miRNA 
degradation.  For instance, in C. elegans, the AGO homolog ALG-1 protects miRNA 
from the 5’-to-3’ exonucleases XRN-1 and XRN-2 thereby stabilizing miRNA abundance 
[128].  However, in D. melanogaster and human cells, extensive pairing between a 
miRNA and its target site induces 3’ end trimming of the miRNA thereby enhancing 
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miRNA decay [128].  Furthermore, miRNA function can also be repressed by target 
mRNA without actually inducing changes in miRNA levels.  Large-scale analysis of 
protein-coding mRNA and miRNA expression profiles has provided evidence that 
thousands of transcripts may actually be acting as target decoys [128].  These so called 
competing endogenous RNA (ceRNA) function by presenting target sites for miRNA 
binding, and titrating them from other target mRNA.  Long non-coding RNA, 
pseudogene RNA, and mRNA can all act as ceRNA [128].  For example, zinc finger E-
box-binding homeobox 2 (ZEB2), contains common miRNA binding sites with the tumor 
suppressor gene PTEN, and increased expression of ZEB2 mRNA was shown to 
sequester repressive miRNA from PTEN, subsequently preventing the miRNA-induced 
repression of PTEN gene expression [133].   
Although our understanding of miRNA function and regulation has increased 
tremendously since the discovery of the first miRNA nearly 20 years ago, many questions 
still remain surrounding the cellular conditions and environmental cues that trigger 
specific miRNA responses.  Provided the increasing roles for miRNA in fine-tuning gene 
expression and coordinating cellular functions, it is reasonable to speculate that nutrient 
availability or nutritional status might also affect miRNA expression in an effort to 
maintain nutrient homeostasis.  Thus characterizing factors that contribute to alterations 
in miRNA biogenesis and processing will enhance our understanding of mechanisms by 
which cells respond to alterations to various situations such as changes in environmental 





microRNA and iron homeostasis 
To date, an investigation into the extent to which dietary iron influences miRNA 
expression or regulation has not been fully described.  Despite the paucity of data in 
terms of altered miRNA expression in response to dietary intake, there is ample evidence 
indicating a potential role for miRNA to regulate both systemic and cellular iron 
homeostasis at multiple points by influencing iron absorption, transport, storage, and 
utilization (see Figure 3).  For instance, iron absorption and utilization may be affected 
by repression of the non-IRE isoform of DMT1 by miR-let-7d [134].  Overexpression of 
miR-let-7d in K562 erythroleukemia cells suppress expression of both DMT1 (non-IRE) 
mRNA and protein levels thereby decreasing the export of endosomal iron for use by the 
cell [134].  The decrease in endosomal iron export elicited an iron-deficient response, as 
evidenced by an increase in TfR expression, decreased ferritin protein abundance, and 














Figure 3.  The potential roles for miRNA to influence iron metabolism. (A) Dietary 
iron absorption.  Non-heme (Fe
3+
) iron may be reduced by duodenal cytochrome B 
(Dcytb) and transported into the cytosol by divalent metal transporter-1 (Dmt1).  Dietary 
heme iron is transported across the apical membrane by mechanisms that remain unclear 
and iron is released from heme by heme oxygenase (Hmox1).  Hmox1 expression is de-
repressed via let-7 targeting the transcriptional repressor Bach1.  Iron that is neither 
stored nor utilized by the enterocyte is exported across the basolateral membrane by 
ferroportin-1 (Fpn) where it is oxidized by hephaestin before being bound to transferrin 
for transport to other tissues.  Iron export can be repressed through direct inhibition of 
Fpn by miR-485-3p.  (B) Cellular iron uptake.  The transferrin-bound iron binds to the 
transferrin receptor (TfR) on the surface of the cell.  The Tf/TfR complex is internalized 
through receptor-mediated endocytosis and upon acidification of the endosome results in 
iron release from Tf.  The Tf/TfR complex can then be recycled back to the plasma 
membrane where the complex is dissociated at a neutral pH.  MiR-320 contributes to the 
regulation of cellular iron uptake by repressing TfR translation to decrease transferrin-
dependent iron uptake.  Endosomal iron released from Tf is carried into the cytoplasm by 
Dmt1, the expression of which is repressed by the miRNA let-7d.  The iron is then either 
stored in ferritin or utilized for iron-containing proteins.  The regulatory action of let-7 on 
Bach1 to de-repress ferritin transcription potentially enhances cytosolic iron storage.  
Utilization of iron is influenced directly by miR-210 which targets the Fe-S cluster 
assembly proteins Iscu1/2 thereby decreasing mitochondrial metabolism.  (C) Systemic 
control of iron homeostasis.  In the liver, Tf interacts with TfR2 and the protein Hfe to 
trigger the bone morphogenetic protein (BMP) and SMAD signaling cascade via 
interaction with the BMP co-receptor hemojuvelin (Hjv) to activate Hamp (hepcidin) 
transcription.  The liver specific miR-122 directly targets HFE and HJV to contribute to 
the regulation of systemic iron homeostasis by decreasing hepcidin mRNA expression.   
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Iron acquisition is also likely regulated by to miRNA-dependent mechanisms.  
For example, overexpression of miR-210 decreases TfR protein abundance in MCF7 cells 
[32].  Furthermore, the enhanced expression of miR-320 decreased the abundance of TfR 
on the plasma membrane and subsequent iron uptake in the lung carcinoma cell line 
A549 [135].  The multi-functional iron-binding protein lactoferrin, along with its 
receptor, is also regulated by miRNA in human cancer cells.  Lactoferrin was 
characterized as a functional target of miR-214 in both HC11 and MCF7 cells [136].  
Interestingly the seed region aligning to miR-214 in the 3’UTR of lactoferrin is very 
highly conserved and identical in the lactoferrin 3’UTR of mouse, rat, pig, goat, camel, 
bovine, and human species [136].  The post-transcriptional expression of the lactoferrin 
receptor is mediated by miR-584 in both Caco-2 cells and in mouse small intestine during 
the perinatal period [137].  Cellular export may also represent a miRNA-mediated 
regulation of iron homeostasis as the only known cellular iron exporter, Fpn, was recently 
shown to be targeted by miR-485-3p [138].   Overexpression of miR-485-3p resulted in 
increased cellular iron levels, while inhibition of miR-485-3p expression decreased 
cellular iron levels.  In the absence of a regulated excretory pathway to rid the body of 
excess iron, the regulation of iron uptake or acquisition is a key point of control in 
maintaining cellular and systemic iron homeostasis.  These exciting findings highlight the 
potential for miRNA to provide an additional means of control to fine-tuning the 
regulation of cellular iron uptake and export. 
 In addition to the regulation of iron uptake and acquisition, miRNA may also 
contribute to the control of cellular iron homeostasis through regulation of iron storage 
via ferritin.  The expression of both forms of the iron storage protein ferritin, FtH and 
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FtL, are significantly higher in human breast cancer cells with a particularly aggressive 
phenotype and correlates with a decreased expression of miR-200b [139].  The de-
repression of FtH expression may be, at least in part, due to the presence of a miR-200b 
seed sequence in FtH [139].  Interestingly, miR-200b has also been shown to correlate 
with dietary zinc depletion and repletion [140].  The functional and physiologic causes 
and consequences of miR-200b regulation in response to alterations in iron and zinc 
status will likely be the focus of future studies.  Iron storage may also be indirectly 
affected by miRNA as both miR-196 and let-7d target the heme-regulated transcriptional 
repressor Bach 1, which results in a de-repression of Bach1 targets such as HMOX1 and 
ferritin [41, 141].  Although ferritin transcription may be reduced via Bach1, the capacity 
for let-7d-dependent repression of Bach1 to de-repress ferritin expression and synthesis 
remains unknown [142].   
 Systemic iron homeostasis is also likely influenced by miRNA expression via the 
liver-specific miR-122 [33].  Inhibition of miR-122 by locked nucleic acid (LNA) 
modification is associated with an increased expression of HFE, HJV, BMPR1A, and 
hepcidin mRNA, all of which contribute to a reduction in both plasma and liver iron, in 
addition to mildly impaired hematopoiesis [33].  In fact, both HFE and HJV are directly 
targeted by miR-122, suggesting that miR-122 could be targeted for therapeutic 
intervention for diseases of iron metabolism [33].  Intriguingly, miR-122 also correlates 
with copper accumulation and the onset of fulminant hepatitis in a rodent model of 
Wilson’s disease [143].  Elevated serum levels of miR-122 are detectable as much as two 
weeks earlier than traditional hepatitis-associated serum markers and therefore may 
represent a potential non-invasive biomarker for early detection of liver disease [143].  
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While it is tempting to postulate that miR-122 may be yet another interesting link 
between iron and copper metabolism, it is important to note that miR-122 compromises 
~70% of all hepatic miRNA expression, and is therefore likely to have numerous hepatic 
regulatory capacities [29, 34].   
 Erythropoietic demand for iron to support the synthesis of hemoglobin is another 
major factor in coordinating iron absorption and utilization, thus miRNA-dependent 
control of erythropoiesis has the potential to contribute to the control of systemic iron 
homeostasis.  Interestingly, many miRNA are highly expressed in the initial stages of 
erythropoiesis and a decline in their expression is required for normal erythrocyte 
proliferation (miR-223), differentiation (miR-150), and maturation (miR-221/222) [144].  
Conversely, miR-96 is actually more abundant in adult reticulocytes than umbilical cord 
blood, and contributes to the regulation of adult erythropoiesis via its direct interaction 
and repression of γ-globin [145].  The therapeutic potential for the manipulation of 
erythropoiesis via targeting of miRNA is the focus of considerable investigation.  
 Though the miRNA-dependent regulation of Fe-S cluster biogenesis and the 
potential effects on cellular iron metabolism via regulation of IRP1 has been suggested, 
the effects of dietary iron intake or iron status on miRNA expression and Fe-S cluster 
assembly have not been extensively investigated.  Current evidence suggests that the 
hypoxia-inducible miR-210 targets Fe-S biogenesis and assembly via the regulation of 
the iron-sulfur cluster scaffold proteins Iscu1/2 [31, 32].  Given the overlap between iron 
and oxygen sensing and maintenance of iron homeostasis, the potential for miR210 to 
repress Fe-S cluster biogenesis, and thereby contribute to the regulation of IRP1 activity 
remains of considerable interest.  To date however, the effect of miR-210 dependent 
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repression of Iscu1/2 expression on IRP1 function and its potential impact on cellular 
iron homeostasis is not yet fully characterized.  
Despite the inherent challenges associated with interrogating the impact of 
nutrient status on miRNA expression and regulation, the pursuit of identifying these 
relationships between nutrient status (e.g., iron deficiency) and miRNA expression is 
warranted as the molecular mechanisms coordinating miRNA regulation and iron 
homeostasis are not yet fully understood or characterized.  Finally, it remains to be 
established whether many of the miRNA demonstrated to affect iron metabolism using 
cell-based or other genetic approaches, such as miR-320 and miR-200b, have 
physiological roles in vivo or in non-transformed cell types, especially in response to 
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Iron is an essential nutrient critical for oxygen transport, DNA synthesis, ATP generation, 
and cellular proliferation.  At the molecular level, iron deficiency (ID) elicits a cascade of 
cellular events aimed at conserving iron for the maintenance of these life-preserving 
functions, but tissue-specific responses and metabolic adaptations to ID are not fully 
understood.  Recently, small regulatory RNA molecules called miRNAs have been 
identified as an important mechanism for regulating various cellular processes.  
Therefore, we sought to determine the extent to which expression of miRNA is regulated 
in response to dietary ID and to examine their potential regulatory capacity in the 
adaptive response to ID.  Utilizing a genome-wide miRNA microarray and a low-density 
PCR array we identified miR-210 as an iron responsive miRNA.  In silico prediction 
programs and reporter assays were then used to predict and validate the iron containing 
heme-protein cytoglobin as a miR-210 target.  Examination of the iron-dependent 
response of the established miR-210 target, Iscu, and the newly established target, 












Iron is an essential, yet potentially toxic nutrient, thus iron homeostasis must be 
tightly regulated to ensure adequacy and prevent overload.  Iron balance is maintained by 
two regulatory systems that function to coordinate iron homeostasis at both systemic and 
cellular levels.  Hepcidin is a key iron regulatory peptide hormone primarily responsible 
for coordinating systemic iron homeostasis by inversely affecting the rate of intestinal 
absorption and/or iron release from macrophages cells based on body iron stores [1].  At 
the cellular level, two iron regulatory proteins (IRP1 and IRP2) coordinate iron 
homeostasis by “sensing” intracellular iron status and accordingly coordinating the 
uptake, storage, and utilization of iron through high affinity RNA binding to iron 
responsive elements (IRE) found in mRNA encoding genes involved in iron metabolism 
[2].  Despite exhibiting similar regulatory functions, the IRP1 and IRP2 themselves are 
regulated quite differently.  While IRP2 is targeted for proteosomal degradation via iron- 
and oxygen-dependent prolyl hydroxylase, the functional role of IRP1 is largely 
dependent on the presence of an iron-sulfur (Fe-S) cluster [3].  Whereas under iron 
deficient conditions the Fe-S cluster is removed and IRP1 functions as an RNA binding 
protein to restore iron homeostasis, under iron replete conditions, the Fe-S cluster is 
stabilized and IRP1 functions as the cytosolic isoform of aconitase (c-acon) [2, 4]. 
Proteins containing Fe-S clusters are found in virtually all organisms, and within 
multiple cellular compartments including the mitochondria, cytosol, and nucleus.  Fe-S 
clusters in proteins act as cofactors that are essential for numerous biologic processes 
including maintenance of iron homeostasis, mitochondrial respiration, electron transfer, 
metabolism, and many other regulatory processes [5].  Skeletal muscle is severely 
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affected by iron deficiency due to the loss of Fe-S proteins, which are essential for 
muscle respiratory function as critical components of the ETC [6, 7].  Interestingly 
however, while the skeletal muscle is severely affected by iron deficiency, the liver 
appears to be relatively resistant to changes in iron status [8, 9].  For example, c-acon 
activity is unchanged in the liver, but significantly decreased in the muscles of iron 
deficient rats [8, 10].  Furthermore, significant reductions in mitochondrial enzyme 
activity, Fe-S enzyme content, and nitrogen fixation 1 homolog (Nfs1 or IscS) protein 
abundance have been reported in skeletal muscle in response to dietary iron deficiency, 
but are largely unaffected in the liver [8, 11, 12].  Given the importance of Fe-S proteins 
in the regulation of iron homeostasis (IRP1) and energy production (i.e., mitochondrial 
aconitase; m-acon), it is of interest to identify and elucidate regulatory factors involved in 
the formation and maintenance of Fe-S clusters, particularly in response to iron 
deficiency. 
In addition to the consequences associated with the loss of Fe-S cluster protein 
activity, a major reason for the side effects observed with iron deficiency is due to the 
essentiality of iron for the biosynthesis of heme, which as the primary component of 
hemoglobin makes oxygen transport possible.  Recent findings have expanded the 
physiologic roles of heme even further as a potential regulator of mRNA stability and 
degradation via the critical role it has been shown to play in microRNA (miRNA) 
processing [13, 14].  miRNA are a class of noncoding RNA approximately 22 nucleotides 
(nt) long that are now predicted to regulate as much as 60% of all protein-coding genes, 
and as such, are anticipated to participate in nearly every biological process within the 
cell [15, 16].  Provided the increasing roles for miRNA to fine-tune gene expression and 
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coordinate cellular functions, it is reasonable to speculate that nutrient availability or 
nutritional status might affect miRNA expression in an effort to maintain nutrient 
homeostasis.  Thus, in addition to understanding the potential impact of iron status on 
miRNA processing, it is of interest to determine the extent to which miRNA contribute to 
the regulation of iron metabolism.    
In fact, the liver-specific miR-122 has already been implicated as a contributory 
factor in systemic iron homeostasis as depletion of miR-122 in mice resulted in decreased 
plasma and liver iron, and mildly impaired hematopoiesis by targeting two transcriptional 
activators of hepcidin, the key systemic iron regulatory hormone [17].  Furthermore, the 
oxygen sensitive miR-210 is an established regulator of the Fe-S cluster assembly 
proteins, iron-sulfur cluster scaffold homolog (Iscu) under hypoxic conditions in cultured 
cells, and thus could play an important role in the control of iron utilization during certain 
environmental stimuli [18, 19].  These findings suggest that miRNA may be key 
regulators in many facets of human iron homeostasis, but to date an investigation into the 
extent to which dietary iron influences miRNA expression or regulation in a whole-
animal has not been fully described.  This evidence for the role of miRNA in modulating 
iron homeostasis is underscored by the fact that miRNA processing is, at least in part, a 
heme-dependent process [13, 14].   
Thus, our primary objectives were to determine the extent to which expression of 
miRNA is regulated in response to ID and to characterize the impact of miRNA 
expression on potential regulatory targets involved in iron metabolism.  In this study we 
have shown that miR-210 expression can be regulated independently of hypoxia as its 
expression is also increased in response to dietary iron deficiency.  Furthermore, we have 
73 
 
identified and validated the hemoprotein cytoglobin as a newly established miR-210 
target.  Lastly, we have demonstrated that tissue-specific responses to iron deficiency 
could potentially be coordinated via miRNA-dependent regulation. This research 
provides novel insight as to how miRNA contribute to the cellular adaptation to iron 
deficiency and the molecular coordination of iron homeostasis.  
Results 
 Iron deficient (ID) animals exhibited a 40% reduction in hemoglobin and a 38% 
reduction in hematocrit after 21 d on the low iron diet compared to their pair-fed (PF) 
controls (Table 1).  Serum iron and liver iron were also reduced 85% and 63%, 
respectively in response to an ID diet (Table 1).  The reduction in iron status 
corresponded with a 1.5-fold and 2-fold increase in spontaneous hepatic IRP1 and IRP2 
RNA binding activity, respectively (Figure 1A and B).  Intriguingly, soleus IRP2 RNA 
binding activity was also increased slightly more than 2-fold, but soleus IRP1 RNA 
binding activity was increased nearly 4-fold (Figure 1 E and F).  Also of note, was the 
lack of change in total IRP1 RNA (Figure 1C and D) binding activity, but a significant, 
albeit small, reduction in total soleus IRP1 RNA binding activity (Figures 1G and H).  
Table 1: Hematologic indices of iron status 
Indices of Iron Status PF ID 
Hemoglobin (d/dL) 13.3 ± 0.1 8.0 ± 0.2 
Hematocrit (%) 43.8 ± 0.5 27.5 ± 1.6 
Serum Iron (μM) 71.4 ± 5.2 10.8 ± 1.4 
Liver Iron (μg/g) 245.9 ± 30.1 92.6 ± 16.0 
Values are means ± SEM, n = 8/group 





Figure 1 Spontaneous and total Iron Regulatory Protein (IRP) RNA binding activity of 
livers (A and C) and muscles (E and G) of pair-fed (PF) and iron-deficient (ID) rats.  
Quantitative analysis of spontaneous IRP1 and IRP2 RNA binding activity, and total 
IRP1 RNA binding activity in livers (B and D) and muscles (F and H).  Values are shown 







Two techniques were employed to identify miRNA that may be regulated in 
response to ID: a genome-wide miRNA microarray, and a low-density PCR miRNA 
array.  Both techniques identified miR-210 as significantly increasing in liver in response 
to an ID diet (See supplemental figures S1 and S2).  The significant increase in hepatic 
miR-210 was then verified by qRT-PCR and northern blot, which both showed a 2-fold 
increase in hepatic miR-210 expression (Figure 2A and S3).  Soleus expression of miR-
210 was also investigated by RT-PCR, and miR-210 was increased 4-fold in the soleus of 
the ID animals (Figure 2).  
 Bioinformatic examination of the mature miR-210 sequence has previously 
revealed that it is highly conserved among most species [20].  Figure 3A shows the 
species conservation of miR-210 for mice, rats, and humans.  In silico prediction of 
potential miR-210 mRNA targets in mouse using the miRWalk target prediction website 
identified 395, 265, and 354 potential miR-210 targets in mice, rats, and humans, 
respectively.  In an effort to narrow our potential targets list we chose to focus on mRNA 
known to be important in iron metabolism and homeostasis.  Taking this approach, we 
identified the heme-containing protein cytoglobin (Cygb) as an interesting potential miR-
210 target.  The species conservation of the miR-210 seed site in Cygb mRNA among 
mice, rats, and humans is shown in figure 3B.  Importantly, the validated miR-210 target 
Iron-Sulfur Cluster Scaffold Homolog (E. Coli) (Iscu) was also identified utilizing these 





Figure 2 Assessment of miR-210 expression by qRT-PCR in livers and muscles of pair-
fed (PF) and iron deficient (ID).  miRNA levels were normalized to the small nuclear 
RNA, SNORD95, as the invariant control.  Values are shown as means ± SEM, n = 











Figure 3  Species conservation of miR-210 stem-loop structure and sequence among 
mice, rats and humans (A).  Species conservation of the miR-210 seed sequence in the 

















The interaction between miR-210 and Cygb was confirmed utilizing reporter 
assays wherein the 3’UTR of the known (Iscu) and predicted (Cygb) miR-210 targets 
were cloned downstream of a luciferase reporter gene, and interaction was confirmed by 
a significant reduction of luciferase activity.  Transfection of a mature 22 nt miRNA 
sequence that is not predicted to regulate any known mRNA was used as a negative 
control (NC).  Transfection of mature miR-210 (mimic) resulted in a 40% and 30% 
reduction in luciferase activity in the Iscu and Cygb constructs, respectively (Figures 4A 
and 4B).  Importantly, transfection of the reporter constructs alone (control), or the 
reporter constructs with the NC miRNA had no effect on Iscu or Cygb luciferase activity 
(Figures 4A and 4B).  To show target specificity, we also transfected luciferase reporters 
containing the 3’UTR of Iscu or Cygb with mutations in the predicted miR-210 seed 
sequences, (Mutant; see table S3) and saw no change in mutant luciferase activity with 
any treatment.  
 To examine the physiologic effects of up-regulated miR-210 expression in vivo, 
we measured the mRNA expression of Iscu and Cygb in the livers and skeletal muscles 
of PF and ID animals.  Hepatic Iscu expression was unchanged, but Cygb expression was 
significantly decreased, albeit mildly, in response to dietary ID (Figure 5A).  No effect on 
Iscu or Cygb mRNA expression was observed in skeletal muscle following 21 d on the 
ID diet (Figure 5B).  To confirm that the livers and muscles were “sensing” iron 
deficiency, the mRNA abundance of iron uptake protein, transferrin receptor (Tfrc) and 
the iron-sensing peptide hormone, Hepcidin (Hamp1) was assessed.  As expected, dietary 
ID resulted in a significant repression (> 99%) in hepatic hepcidin mRNA abundance and 




Figure 4  Validation of Iscu and Cygb as miR-210 target genes.  HEK293T cells were 
co-transfected with the pMIR-REPORT β-Gal control vector and the pMIR-REPORT 
Luciferase vector containing either the wild-type (WT) or mutated (Mutant) 3’UTR of 
Iscu (A) or Cygb (B) (see Supplemental Table 1 for localization of predicted miR-210 
binding sites and mutated sequence).  Cells were then treated with vehicle (Control), a 
miR-210 mimetic (Mimic) or a negative control (NC) miRNA with no known predicted 
mRNA targets.  After 24 h luciferase activity was measured and normalized to β-
Galactose activity.  Experiments were performed at least three times, and results are 
presented as fold-change ± SEM of the control transfected cells.  *Statistical difference 

















Figure 5  Expression Iscu and Cygb mRNA in the liver (A) and muscle (B) of pair-fed 
(PF) and iron-deficient (ID) rats.  Expression of the iron-responsive hepcidin (Hamp1) 
and transferrin receptor (TfRc) were assessed as positive controls in liver and muscle, 
respectively.  mRNA levels were normalized to Cyclophilin B (Cyclo) as the invariant 
control.  Numbers beneath the gene names indicate Cq value obtained for the PF group.  
Values are shown as means ± SEM, n = 8/group.  *Statistical significance between PF 

















miRNA induced alterations in target gene expression to physiologic cellular 
events, such as reduced nutrient availability are often times mild at best, and the timing of 
these responses are not fully characterized.  Therefore, because the ID animals were only 
moderately anemic, and because tissues were only harvested at one time point, it is 
possible that the degree of miR-210 dependent regulation of Iscu and Cygb was too mild 
to be observed in our physiological model.  Likewise, an adaptation to the reduced iron 
status may have already occurred, and as such Iscu and Cygb expression levels could 
have normalized.  To sidestep these potential confounding factors we examined Iscu and 
Cygb expression in response to iron depletion in the mouse liver and muscle derived cell 
lines, Hepa1-6 and C2C12, respectively.  Following 18 hr of treatment with the iron 
chelator, desferrioxamine (DFO), miR-210 expression was increased 6- and 7-fold in 
Hepa1-6 and C2C12 cells, respectively.  The DFO induced miR-210 expression 
coincided with a significant repression in Iscu and Cygb mRNA abundance in C2C12 
cells, and a trend toward the decreased expression of Iscu in Hepa1-6 abundance (P = 












Figure 6  Expression of Iscu and Cygb mRNA in mouse hepatoma (Hepa1-6) cells (A) 
and mouse myoblast (C2C12) cells (B).  Cells were left untreated (Control) or were 
treated with 100μM  desferrioxamine (DFO) for 18 hr.  mRNA levels were normalized to 
Cyclophilin B (Cyclo) as the invariant control.  Numbers beneath the gene names indicate 
Cq value obtained for the control cells.  Expression of the iron responsive transferrin 
receptor (Tfrc) was assessed as a positive control in both cell types.  Experiments were 
performed at least three times, and values are shown as means ± SEM, n =3/group.  


















Anemia was confirmed in the ID animals following 21 d on a low iron diet by 
significant reductions in hemoglobin, hematocrit, serum iron, and liver iron.  Tissue iron 
deficiency was further evidenced by significant increases in hepatic and skeletal muscle 
IRP RNA binding activity.  It is well established that the effects of iron deficiency on 
skeletal muscle are much more pronounced than other tissues [6-8, 22].  Here too we 
show IRP1 binding activity in the livers of iron-deficient animals only increases to about 
10% of the available pool of IRP1 protein, while in skeletal muscle, over 50% of the 
available IRP1 protein pool is converted to the active IRE binding form in response to ID.   
Also, while total IRP1 RNA binding activity was not affected by ID, skeletal muscle total 
RNA binding activity was significantly reduced. 
Although interconversion of IRP1/c-acon via assembly and disassembly of the Fe-
S cluster is thought to be the primary mechanism through which the protein’s activity is 
regulated, IRP1 activity can also be regulated independently of iron by other means 
including oxidative stress and post-translational modification [23-25].  For example, 
when Fe-S cluster assembly is impaired, IRP1 activity is regulated through iron-
dependent protein degradation [24].  Current evidence is supportive of the hypothesis that 
miRNA could be involved in the maintenance of iron homeostasis, as well as in the tissue 
specific responses to alterations in iron status [26].  Here we show that the hypoxia 
regulated miR-210 is also regulated in an iron-dependent manner through increased 
expression of the mature miR-210 in the livers and skeletal muscles of ID animals. These 
findings are very interesting as miR-210 has been demonstrated to be directly involved in 
iron utilization and regulatory pathways through direct interaction with the Fe-S cluster 
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assembly proteins, Iscu1/2, and because of the intricate relationship between oxygen and 
iron homeostasis [18, 21].   
Excitingly, we have also identified and validated a novel miR-210 target, Cygb 
that has also been demonstrated to be intimately involved in iron utilization and hypoxic 
signaling pathways.  It is logical then that oxygen carrying hemoprotein Cygb may be 
regulated by a hypoxic and iron-dependent miRNA in an effort to coordinate oxygen and 
iron utilization with availability [27].  For example, with insufficient iron availability, 
hemoglobin production falls, red blood cell formation is diminished, and oxygen carrying 
capacity of the blood is reduced [28].  Conversely, when oxygen availability is limited, 
red blood cell formation is enhanced in an effort to increase oxygen transport and tissue 
oxygen availability for maintenance of oxygen utilization [29, 30].  However, under iron-
deficient conditions, enhanced red blood cell production would only further deplete low 
iron stores.  It has previously been established that IRP can down-regulate hypoxic 
signaling, presumably in an effort to conserve diminishing iron stores [31, 32].  The iron-
dependent regulation of miR-210 may then serve as a means of even further fine-tuning 
these regulatory processes in an effort to maintain a physiologic equilibrium between 
oxygen and iron usage with availability.  
Based on the findings presented herein, it is tempting to postulate the observed 
tissue-specific effects on IRP1 RNA binding activity are the result of iron-dependent 
modulation of miR-210 expression and the potential downstream effects the Fe-S cluster 
machinery.  In this study however, we did not observe a significant repression in Iscu 
mRNA abundance in liver or skeletal muscle.  In mammals, miRNA are thought to 
primarily regulate gene expression via transcript degradation, however miRNA can also 
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act via translational repression [33].  Although not measured here, it is possible then that 
even though mRNA levels were unchanged, Iscu protein abundance may still have been 
decreased in response to dietary ID.  Contesting the idea of translation repression versus 
transcript degradation however, were our findings that iron depletion in Hepa 1-6 and 
C2C12 did result in decreased Iscu mRNA abundance.   Therefore, the mode of in vivo 
miR-210 mediated Iscu repression and the physiologic significance of this regulation in 
response to ID warrants further investigation. 
The hypoxic and iron deficient induction of miR-210 and subsequent repression 
of Iscu likely represents an adaptive cellular response to repress mitochondrial respiration 
and limit iron utilization.  It is somewhat counterintuitive that the iron-deficient induction 
of miR-210 would down-regulate Cygb expression, a well-established hypoxia induced 
protein [27].  Although the physiologic relevance of this response is not abundantly clear, 
several possibilities for this stimulus-dependent response exist.  For example, it has been 
proposed that miR-210 is up-regulated to repress genes that are no longer necessary 
under hypoxic conditions, and that it remains elevated even after homeostasis has been 
restored to ensure maintenance of this adaptive response [20, 34].  Iron deficiency does 
result in decreased oxygen carrying capacity of the blood, and thus reduced oxygen 
delivery to tissues [35, 36].  In this study, tissues were only harvested at one time point, 
so it is possible that an adaptive responsive to changes in cellular oxygen tensions has 
already occurred, and we are observing residual miR-210 up-regulation for adaptive 
maintenance purposes.  Once oxygen homeostasis has been restored, enhanced Cygb 
expression would no longer be necessary, thus a miR-210 mediated repression of Cygb 
would be a logical physiologic response.   
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Another explanation for elevated levels of miR-210 and Cygb under hypoxic 
conditions, but miR-210 induced Cygb repression under iron-deficient conditions could 
be the result of competitive inhibition of Cygb repression by other miR-210 targets in 
response to hypoxia.  Recently, multiple studies have shown that potentially any mRNA 
with miRNA targets sites can function as a competing endogenous RNA (ceRNA) [33].  
As mentioned earlier, miR-210 has predicted binding sites in hundreds of different genes, 
many of which may also be up-regulated under low oxygen conditions.  Therefore, 
hypoxic induction of these potential miR-210 targets could effectively titrate miR-210 
away from Cygb in the initial stages of hypoxia, preventing Cygb repression until 
hypoxic adaptation has occurred and cellular homeostasis has been restored.  The newly 
defined long non-coding RNA (lncRNA) have been called prime candidates to serve as 
miRNA decoys, and may represent an as yet unidentified means of miR-210 regulation as 
well since most target prediction programs don’t include lncRNA in their target search 
algorithms [33].   
Ever since miR-210 was first demonstrated to target Iscu, it has been 
hypothesized that miR-210 could play a significant role in the regulation of Fe-S cluster 
containing proteins, such as IRP1 [18, 21].  While the findings of this study do not refute 
this hypothesis, they don’t provide overwhelming evidence in support of it either.  Here 
we show that even though miR-210 was up-regulated to a higher degree in skeletal 
muscle than in liver, and that total IRP1 RNA binding activity was decreased in skeletal 
muscle, no effect was observed on Iscu expression in our animal model.  However, iron 
depletion in the muscle derived C2C12 cell line did result in significant increase in miR-
210 expression and a corresponding repression of Iscu mRNA abundance.  Thus, the 
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functional consequences of miR-210 mediated Iscu repression and Fe-S cluster protein 
regulation in response to iron deficiency remain unclear, but will likely be the subject of 
future investigations.  We were able however to identify and validate a novel miR-210 
target, Cygb, and demonstrate its functional repression in the livers of iron deficient 
animals, as well as in the C2C12 cell line.  These findings are exciting as they extend the 
known functional roles of miR-210, and provide some of the first substantial evidence for 
the contribution of miRNA in coordinating molecular iron homeostasis in a physiologic 
model of dietary iron deficiency. 
Materials & methods 
Weanling 21 d old male Sprague-Dawley rats (Harlan Sprague Dawley, Indianapolis, IN) 
weighing approximately 50 g were fed a purified powdered control (C) diet containing 40 
mg Fe/kg for 3 d to acclimate to laboratory conditions and facilities.  On d 4 (or d 0 of the 
experimental period), rats were randomly assigned to one of three treatment groups (n = 
8/group) for the 21 d:  iron deficient (ID; < 5 mg Fe/kg diet), control (C; 50 mg Fe/kg 
diet), or pair-fed (PF; fed the C diet at the level of intake of the ID group).  The diets 
were purchased from Harlan Teklad (Madison, WI; C-TD.89300 and ID-TD.80396) and 
based on the recommendations from the American Institute of Nutrition’s 1976 Standards 
for Nutritional Studies [37].  The inclusion of a PF group is necessary to attribute 
observed biological effects to a diminished iron status and not an overall decrease in 
overall food intake [38, 39].  For this reason, the PF group is the more appropriate control 
for many of the experiments described below and will be used as such. 
Animal Care: All animal studies were approved by the Oklahoma State University 
Institutional Animal Care and Use Committee.  Animals were housed at the OSU 
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Laboratory Animal Research Facility and maintained on a 12 h light/dark cycle in a 
temperature- and humidity- controlled environment in individual wire-bottomed cages to 
prevent coprophagy [40].  Upon completion of the treatment period, animals were 
anesthetized with a mixture of ketamine/xylazine (75 mg ketamine and 7.5 mg 
xylazine/kg body weight).  Blood was collected via the abdominal aorta for plasma and 
serum preparation.  Following cardiac exsanguinations, tissues were removed and 
immediately frozen in liquid nitrogen.   
Assessment of Iron Status:  Hemoglobin and hematocrit were assessed by Antech 
Diagnostics (Dallas, TX).  Plasma and liver iron were determined using an ELAN 9000 
ICP-Mass Spectrometer (PerkinElmer, Downers Grove, IL). 
Cell culture:  Mouse hepatoma (Hepa1-6) and myoblast (C2C12) cell lines (obtained 
from ATCC, Manassas, VA) were cultured in DMEM containing 10% heat inactivated 
fetal bovine serum, 5% L-glutamine, and an antibiotic-antimycotic (Cellgro, Herndon, 
VA) at 37ºC in 5% CO2.  Cells were treated with 100μM of the iron chelator, 
desferrioxamine, for 18 hr to induce iron deficiency.  
IRP RNA Binding Activity:  Ferritin cDNA used for IRE synthesis has been previously 
described by Eisenstein et al. [41].  Briefly, a 73 nucleotide [
32
P]-labeled RNA containing 
the IRE was produced by T7 RNA polymerase, and gel purified though a 10% 
acrylamide 8M urea gel before determination of specific activity.  Cytosolic fractions 
from liver and muscle were obtained by homogenizing the frozen tissues in 3 volumes 
HDGC buffer (20 mM HEPES, 1 mM dithiothreitol, 10 % glycerol, and 2 mM citrate) or 
HDGK (20 mM HEPES, 1 mM dithiothreitol, 10 % glycerol, and 175 mM potassium 
chloride), respectively, and collecting the supernatant after centrifugation at 100,000 x g.  
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Protein concentration was determined using the bicinchoninic acid (BCA) protein assay 
[42]. 
Spontaneous IRP1 and IRP2 RNA binding activity was assessed by incubating 5 
µg cytosolic extract for 10 minutes on ice with saturating levels of [
32
P]-labeled RNA 
followed by electrophoresis through a 4% polyacrylamide (60:1 
acrylamide/bisacrylamide) at 150 V for ~ 75 min.  Total IRP1 RNA binding activity was 
measured by incubating 1 µg cytosolic extract with saturating levels of [
32
P]-labeled 
RNA in the presence of 6% β-mercaptoethanol at room temp for 20 min, followed by 
electrophoresis as described above.  Gels were visualized using a Bio-Rad Phosphor K 
imaging screen and Personal Molecular Imager FX imaging system (Bio-Rad, Hercules, 
CA) for assessment of RNA binding with OptiQuant Acquisition & Analysis software 
(Packard Bioscience, Meridien, CT).   
RNA Extraction:  Total RNA was isolated from liver and skeletal muscle using RNA 
STAT-60 (TelTest, Inc., Friendswood, TX) following the manufacturer’s protocol.  RNA 
concentration was determined by spectrophotometric analysis at OD254 using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA).  Sample purity and 
integrity were determined by spectrophotometric analysis (OD260/280 > 1.8 and OD260/230 > 
1.0) and by agarose gel electrophoresis, respectively. 
miRNA Microarray Analysis:  Total RNA from the livers and soleus muscles of ID and 
PF animals were comparatively analyzed by LC Sciences (Houston, TX).  A PF and an 
ID sample was compared on each miRNA array chip for a total of 8 chips each for liver 
and muscle analysis (n=4/group, n=8/tissue). Individual chip data was then combined, 
and an in-depth statistical analysis of microarray data was conducted by LC Sciences. 
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miRNA focused PCR array and qPCR:  Alterations in liver miRNA expression were also 
examined using the miFinder miRNA PCR array for rat and miScript Primer Assays for 
individual mature RNA (SABiosciences, Valencia, CA).  Briefly, 500 ng total liver and 
soleus RNA was reverse transcribed using the miScript II RT kit (SABiosciences), which 
selectively facilitates conversion of mature miRNA to cDNA to minimize background 
interference from longer RNA.  The cDNA was then used as a template for qPCR 
according to the array instructions using SYBR green chemistry on an ABI 7900HT 
system (Applied Biosystems, Grand Island, NY).  Array data was analyzed using 
miScript miRNA PCR Array Data Analysis Software at  
http://www.sabiosciences.com/mirnaArrayDataAnalysis.php. Relative quantification of 
each miRNA was determined by normalizing to RNU6 and 4.5S, then comparing PF and 
ID groups using the 2
-ΔΔCt
 method.   Expression changes of the mature miR-210 were 
validated in liver and assessed in muscle, and assessed in Hepa1-6 and C2C12 cells using 
miScript Primer Assay with cDNA synthesized as above and analyzed using the 2
-ΔΔCt
 
method with the small nuclear RNA, SNORD95 as the invariant control.  For target 
mRNA relative expression determination, total liver and soleus RNA was first DNase I 
(Roche, Indianapolis, IN) treated and then reverse transcribed using SuperScript II 
(Invitrogen, Carlsbad, CA).  Quantitative RT-PCR was performed using an ABI 7900HT 
system (Applied Biosystems, Foster City, CA) and SYBR green chemistry.  Relative 
mRNA expression was determined using the 2
-ΔΔCt
 method with Cyclophilin B (Cyclo) as 
the invariant control. 
Bioinformatics approach for identification of potential miRNA targets:  To identify 
potential miRNA/mRNA interactions the publically available databases miRWalk 
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(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) and miRanda 
(www.microRNA.org), were utilized.  The miRWalk program employs its own algorithm 
and additionally provides a comprehensive output of miRNA/mRNA interaction 
predictions from 8 established miRNA target prediction programs [43].  The miRanda 
program uses the mirSVR regression method for predicting potential miRNA/mRNA 
interactions, and has been described elsewhere [44].  In an effort to improve the 
likelihood of predicting a true target, predictions were restricted to the identification of 
potential targets in at least 3 of the available databases, with a minimum seed length of 7 
nt and a p-value < 0.05.    
Reporter Assays:  Target 3’UTRs were amplified from mouse genomic DNA and cloned 
into the pMIR-REPORT Luciferase vector (Ambion, Austin, TX) between the 
SpeI/HindIII sites.  Site directed mutagenesis of the miRNA seed sequences were 
performed by Mutagenex (Somerset, NJ).  (See supplemental table S3 for predicted and 
mutated seed sequences).  All constructs were verified by sequencing.  HEK293T cells 
were plated at 3 x 10
4
 cells/well and transfected 24 hours later with 50 nM miRVana 
miRNA mimic or scrambled control (Ambion), 100 ng of the pMIR-REPORT Luciferase 
vector containing the wild-type or mutant 3’UTR, and 50 ng of pMIR-REPORT β-gal 
Control Plasmid.  Luciferase and β-galactosidase activities were assessed 24 hours after 
transfection using a Synergy HT microplate reader and Gen5 v 2.01 software (BioTek; 







The significance of treatment effects was determined by ANOVA and Student’s T-test 
techniques using SPSS software version 17.0 (IBM-SPSS, IL).  All tests were done at the 
95% confidence level (alpha = 0.05).  Descriptive statistics were calculated on all 
variables to include, mean, standard deviation, and standard error of the mean.  
Microarray results were log-transformed and ranked by log-change between PF and ID 
samples.  The results from each chip were combined by group and analyzed for 
significance using Student’s T-test 
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MICRORNA PROFILING REVEALS MIR-181D CONTRIBUTES TO THE METABOLIC 
ADAPTATION TO IRON DEFICIENCY 
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In addition to their central role in cellular energy metabolism and ATP generation, 
mitochondria are essential for heme biosynthesis and biogenesis of iron-sulfur (Fe-S) 
clusters.  Thus, mitochondrial iron demand is a key effector in the maintenance of cellular 
iron homeostasis.  Insufficient cellular iron impairs mitochondrial function and disrupts 
oxidative metabolism, though the mechanisms for coordinating energy metabolism, 
mitochondrial iron utilization, and cellular iron availability are only beginning to be 
understood.  Recent evidence suggests that post-transcriptional and post-translational 
processes are essential for mitochondrial adaptation to changes in cellular conditions.  
MicroRNA (miRNA) are a class of small regulatory molecules that mediate post-
transcriptional gene regulation to assist in fine-tuning the response to changes in the 
cellular environment.  Further, miRNA may also function as nutrient sensors and 
regulators of mitochondrial activity, and thus are likely candidates for coordinating 
mitochondrial function with iron availability.  In this study, we examined changes in 
miRNA expression in response to iron deficiency and found the mitochondrial associated 
miRNA, miR-181d is significantly elevated in the livers and skeletal muscles of iron 
deficient animals.  Further bioinformatic analyses and in vitro reporter assays confirmed 
that miR-181d contributes to the regulation of two mitochondrial proteins important for 
iron trafficking and cellular energy metabolism, the mitochondrial iron transporter 
mitoferrin 1 (Slc25a37) and the rate-limiting enzyme of β-oxidation in the muscle 
mitochondria, carnitine palmitoyltransferase 1B (Cpt1b).  These findings reveal that 
expression of miR-181d is subject to regulation by iron status and that this miRNA may 




As a result of their central roles in Fe-S cluster biogenesis and heme production, 
mitochondria are a major site for cellular iron utilization [1, 2].  Indeed, iron is required 
for mitochondrial energy production through both heme- (cytochromes) and Fe-S cluster-
containing proteins (aconitase).  Thus, it is important that cellular iron homeostasis and 
mitochondrial iron availability be tightly coordinated to preserve optimal mitochondrial 
function.  Recently, the central regulators of cellular iron homeostasis, iron regulatory 
proteins (IRP) 1 and 2, were identified as playing an essential role in mitochondrial iron 
availability as their presence in the cytosol is necessary to protect the mitochondria from 
detrimental iron deficiency [3].  However, the signaling mechanisms coupling cytosolic 
and mitochondrial iron homeostasis are not fully clear, except to suggest that cytosolic 
iron metabolism is strongly influenced by mitochondrial iron demand [1, 2].   
Iron deficiency progresses in stages beginning with the depletion of iron stores, 
followed by diminished erythropoiesis, and finally a reduction in hemoglobin production, 
the hallmark of iron deficiency anemia [4].  Symptoms of iron deficiency include 
weakness, fatigue, and a reduced capacity to transport oxygen as a result of lowered 
hemoglobin levels [5].  Indeed, many of the negative effects associated with iron 
deficiency arise from the reduced oxygen carrying capacity of the blood as well as the 
compromised respiratory capacity of the skeletal muscle as a result of insufficient iron for 
TCA cycle and electron transport flux [6].  Despite compensatory mechanisms employed 
by the liver, such as increasing non-iron-containing enzyme activities, a metabolic shift 
occurs in which the body becomes decreasingly reliant on β-oxidation for energy 
production, and subsequently more dependent on glucose utilization and gluconeogenesis 
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[7-10].  The decrease in muscle oxidation activity is the result of decreased mitochondrial 
enzyme content, rather than decreased enzyme activity, suggestive of insufficient 
mitochondrial iron availability to support heme biosynthesis and production of iron-sulfur 
(Fe-S) clusters for Fe-S containing proteins located in either the mitochondria or the 
cytoplasm [6, 11]. 
Mitochondrial activity and function, and thus iron needs, are largely influenced by 
changes in the cellular environment.  When cellular iron status is impaired and iron 
availability is limiting, both mitochondrial protein levels and oxidative capacity decrease 
[6, 11].  In addition to these changes in mitochondrial enzyme function, mitochondrial 
biogenesis is also impaired in response to iron deficiency [6, 11, 12].  Current evidence 
suggests that post-transcriptional and post-translational processes are critical for 
mitochondrial adaptation to iron limiting conditions [12, 13].  A potentially important 
post-transcriptional mechanism contributing to this mitochondrial adaptation involves 
microRNA (miRNA).  MiRNA are a class of small (~22-nt) non-coding RNA that 
function to fine-tune gene expression through mechanisms involving enhanced mRNA 
decay and/or translational repression [14-16].  Because miRNA expression may be 
affected by nutrient availability, miRNA-dependent control of iron metabolism is an 
attractive model to explain some of the observed changes in mitochondrial function 
associated with iron deficiency [17, 18].   
Furthermore, in vitro studies have demonstrated that the oxygen sensitive 
miRNA-210 can regulate cellular metabolism via direct inhibition of the Fe-S cluster 
assembly proteins (ISCU1/2) [19, 20].  Also, inhibition of the liver-specific miRNA-122 
has established its importance in both lipid and iron homeostasis in mice, and provided 
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additional evidence for the role of miRNA to function as important regulators in the 
response to alterations in nutrient homeostasis [21, 22].  To date however, a 
physiologically-based study investigating the potential for dietary iron deficiency to 
influence miRNA expression and regulation has not been conducted.  Furthermore the 
roles of miRNA in the regulation of iron homeostasis and the adaptive response to 
deficiency remain unknown.  Thus our primary objectives were to determine the extent to 
which expression of miRNA is regulated in response to dietary iron deficiency and to 
characterize the impact of miRNA expression on potential regulatory targets involved in 
iron homeostasis and energy metabolism.  To do this we first examined the miRNA 
profiles of iron-adequate and iron-restricted conditions in animals.  We then focused on 
miR-181d, a miRNA with direct implications in the iron-deficient response, and were 
able to identify and validate two novel miR-181 targets critical for the metabolic 
adaptation to iron deficiency.  
Methods 
Weanling 21 d old male Sprague-Dawley rats (Harlan Sprague Dawley, 
Indianapolis, IN) weighing approximately 50 g were fed a semi-purified powdered 
control diet containing 40 mg Fe/kg for 3 d to acclimate to laboratory conditions and 
facilities.  On d 4 (or d 0 of the experimental period), rats were randomly assigned to one 
of two treatment groups (n = 8/group) for 21 d:  iron deficient (ID; < 5 mg Fe/kg diet) or 
pair-fed (PF; fed the control diet at the level of intake of the ID group).  The diets were 
purchased from Harlan Teklad (Madison, WI; C-TD.89300 and ID-TD.80396) and based 
on the recommendations from the American Institute of Nutrition’s 1976 Standards for 
Nutritional Studies [23].  The use of a PF control group is necessary because rats fed an 
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ID diet may consume as much as 15% less then animals fed a control diet ad libitum [24, 
25].  Use of a PF control then allows us to attribute observed biological effects to a 
diminished iron status and not an overall decrease in overall food intake.   
Animal Care: All animal protocols were approved by the Oklahoma State University 
Institutional Animal Care and Use Committee.  Animals were housed at the OSU 
Laboratory Animal Research Facility and maintained on a 12 h light/dark cycle in a 
temperature- and humidity-controlled environment in individual wire-bottomed cages.  
Upon completion of the treatment period, animals were anesthetized with a mixture of 
ketamine/xylazine (75 mg ketamine and 7.5 mg xylazine/kg body weight).  Blood was 
collected via the abdominal aorta for serum preparation.  Following cardiac 
exsanguination, the liver and soleus were removed and snap-frozen in liquid nitrogen.   
Assessment of Iron Status:  Hemoglobin and hematocrit were determined by Antech 
Diagnostics (Dallas, TX).  Non-heme liver iron concentration was determined by 
colorimetric assay as previously described [26]. 
RNA Extraction:  Total RNA was isolated from liver and soleus (skeletal muscle) using 
RNA STAT-60 (TelTest, Inc., Friendswood, TX) following the manufacturer’s protocol.  
RNA concentration was determined by spectrophotometric analysis at OD260 using a 
Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA).  For each 
sample RNA purity and integrity were determined in-house by spectrophotometric 
analysis at OD260/280, and by agarose gel electrophoresis, respectively. Samples that met 
pre-determined quality standards (OD260/280 > 1.8 and OD260/230 > 1.0) were selected for 
sequencing, and RNA concentration and integrity were further assessed by Illumina, Inc. 
(Sand Diego, CA) using an Agilent Bioanalyzer (Palo Alto, CA). 
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Library Construction:  Library construction was performed by Illumina, Inc. (San Diego, 
CA) using the Small RNA Sample Preparation Alternative version 1.5 Protocol (Part # 
15002615 Rev. A).  First, total RNA (N=8; n=4 from the ID group and n=4 from the PF 
group) isolated from liver as described above was ligated to the v1.5 small RNA 3’ and 
5’ adapters.  Next, the ligated fragments were purified by polyacrylamide gel 
electrophoresis and selected based on size before recovery by column centrifugation.  
The purified ligation products were then placed in an 8-channel flow cell lined with 
oligonucleotides that bind to the ligated adaptor, reverse-transcribed, and PCR-amplified 
to specifically enrich for the fragments containing both 5’ and 3’ adaptors.  Finally, size, 
purity, and concentration of generated libraries were assessed to evaluate quality before 
further sequencing analysis using an Agilent Technologies 2100 Bioanalyzer (Santa 
Clara, CA). 
miRNA Sequencing:  Small RNA libraries were sequenced using a Genome Analyzer IIx 
(Illumina, Inc., San Diego, CA).  Raw sequencing reads were generated in FASTA 
format to facilitate downstream analysis and application.  
Bioinformatics for identification of differentially expressed miRNA:  In an effort to 
obtain unbiased and accurate results for identification of both differentially expressed and 
novel miRNA, raw sequencing data was analyzed independently using three previously 
validated bioinformatics approaches [27-29].  The software packages miRExpress and 
Pipeline (Illumina, Inc., San Diego, CA) were used to align sequencing reads against the 
rat genome and identify the differentially expressed sequences based on annotated 
miRNA sequences.  The third technique employed a combination of alignment and 
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structural analytic bioinformatic techniques to generate a miRNA expression profile for 
each biological sample. 
 The computational analysis using miRExpress was performed using the software 
package miRExpress v 17 (http://mirexpress.mbc.nctu.edu.tw/) and the OSU High 
Performance Computing Center.  miRExpress uses the raw sequencing data provided 
from sequencing output to develop a miRNA expression profile [29].  First, identical 
reads were merged into a unique read, and then each unique read is counted.  Next, 
unique reads were trimmed based on the presence and location of a full or partial adaptor 
sequence.  In the third step, sequences were aligned to the sequences of known mature 
miRNA using the sequencing data available from miRBase (Release 18.0), a database of 
all currently published and annotated miRNA sequences.  Lastly, miRNA expression 
profiles were created by computing the sum of read counts for each miRNA according to 
the matched alignments from the third step [29]. 
The data were also analyzed for read quality and miRNA expression profiles by 
using Illumina Pipeline software.  This software performs the alignment process using the 
Efficient Large-Scale Alignment of Nucleotide Databases, followed by a post-sequencing 
analysis from these aligned reads using the Consensus Assessment of Sequence and 
Variation (CASAVA) Software package.  CASAVA was then used to generate 
descriptive statistics such as percentage chromosome coverage, and read counts for 
exons, genes, and splice junctions.  The last step in this approach was the utilization of 
the software tool, Flicker v 3.0, which employs a nearly identical four step process to that 
described above for miRExpress to generate a miRNA expression profile. 
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 The third computational analysis utilized has been previously described [27].  
First, all miRNA reads without perfect matches to the 5’ end of the adaptor sequences 
were removed.  Then reads were aligned using Repbase (version 14, obtained from 
http://www.girinst.org), and known noncoding RNAs (rRNAs, tRNAs, snRNAs, 
soRNAS, etc.) identified by Rfam (http://www.sanger.ac.uk/Software/Rfam/ftp.shtml) 
with National Center for Biotechnology Information BLASTn were removed [30].  
Following removal, unique sequences between 18 and 28 nt were mapped using BLASTn 
searches versus the rat genome and aligned to known miRNA sequences using miRBase 
(version 18; http://microrna.sanger.ac.uk/) to identify conserved miRNA homologs.   
Bioinformatics approach for identification of potential miRNA targets:  To identify 
potential miRNA/mRNA interactions the publicly-available database miRWalk 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) was utilized [31].  The 
miRWalk program employs its own algorithm and additionally provides a comprehensive 
output of miRNA/mRNA interaction predictions from 8 established miRNA target 
prediction programs.  In an effort to improve the likelihood of predicting a bona fide 
target, predictions were restricted to the identification of potential targets in at least 3 of 
the available databases, with a minimum seed length of 7 nt and a p-value < 0.05.   
Quantitative Real-Time PCR (qPCR):  Iron-dependent alterations in miR-181d 
expression in liver and muscle were assessed using qPCR using miScript Primer Assays 
(SABiosciences, Valencia, CA).  Briefly, 500 ng total RNA from liver and soleus was 
reverse-transcribed using the miScript II RT kit (SABiosciences), which selectively 
facilitates conversion of mature miRNA to cDNA to minimize background interference 
from longer RNA.  The cDNA was then used as a template for qPCR according to the 
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manufacturer’s instructions using SYBR green chemistry on an ABI 7900HT system 
(Applied Biosystems-Life Technologies, Grand Island, NY).  Data were analyzed using 
the 2
-ΔΔCt
 method with the snRNA, SNORD95 as the invariant control.   For target 
mRNA relative expression determination, total liver and soleus RNA was first treated 
with DNase I (Roche, Indianapolis, IN) and then reverse-transcribed using SuperScript II 
(Invitrogen, Carlsbad, CA).  Quantitative PCR was performed using an ABI 7900HT 
system (Applied Biosystems, Foster City, CA) and SYBR green chemistry.  Relative 
mRNA expression was determined using the 2
-ΔΔCt
 method with Cyclophilin B (Cyclo, 
also known as peptidyl isomerase B or Ppib) as the invariant control. 
Reporter Assays:  Target 3’UTRs were amplified from mouse genomic DNA and cloned 
into the pMIR-REPORT Luciferase vector (Ambion, Austin, TX) between the 
SpeI/HindIII sites.  Site-directed mutagenesis of the miRNA seed sequences in 3’UTRs 
were performed by Mutagenex (Somerset, NJ).  (See supplemental table S1 for wild-type 
and mutagenized seed sequences). All constructs were verified by sequencing.  
HEK293T (ATCC, Manassas, VA) cells were plated at 3 x 10
4
 cells/well in a flat-bottom 
96-well plate and transfected after 24 hr with 50 nM miRVana miRNA mimic or 
scrambled control (Ambion), 100 ng of the pMIR-REPORT Luciferase vector containing 
the wild-type or mutant 3’UTR, and 50 ng of pMIR-REPORT β-gal Control Plasmid.  
Luciferase and β-galactosidase activities were assessed 24 hr after transfection using a 
Synergy HT microplate reader and Gen5 v 2.01 software (BioTek; Winooski, VT).  




The significance of treatment effects were assessed by Student’s T-test techniques using 
SPSS software version 17.0 (IBM-SPSS, Chicago IL).  All tests were performed at the 
95% confidence level (alpha = 0.05).  Descriptive statistics were calculated on all 
variables to include, mean, standard deviation, and standard error of the mean.  
Sequencing data were analyzed by obtaining read frequencies from PF and ID samples, 
and comparing them by Mann-Whitney U.  The results from each chip were combined by 
group and analyzed for significance using Student’s T-test. 
Results 
As expected, ID animals exhibited a ~ 40% reduction in both hemoglobin and 
hematocrit, and a 57% reduction in non-heme liver iron after 21 d on the low iron diet 
compared to their PF controls (Figure 1).  Importantly, and in agreement with our 
hypothesis, this reduction in iron status resulted in significant alterations in hepatic 
miRNA expression (Figure 2).  Interestingly, the three different bioinformatic analyses 
that were performed resulted in unique miRNA expression profiles between the PF and 
ID groups.  In an effort to ensure accuracy, we chose to further examine miRNA that 
were identified as being differentially expressed by all three approaches (Figure 2).  
Additionally, only differentially-expressed miRNA that were conserved among mice, 
rats, and humans, were chosen as potential candidates for validation and target prediction.  
One miRNA candidate meeting the criteria described above was miR-181d.  
Differential expression of hepatic miR-181d was then confirmed by qRT-PCR, and was 




Figure 1  Hematologic indices of iron status.  Hemoglobin (A), hematocrit (B), and non-
heme liver iron (C) concentrations in pair-fed (PF) and iron deficient (ID) rats.  Vales are 






















Figure 2  Venn diagram of miRNA identified as being differentially regulated in 
response to dietary iron deficiency by three independent bioinformatic analyses.  miR-
181d is highlighted because of it was found to be expressed in both liver and muscle and 









fold in the livers and ~ 2.5 fold in the soleus muscles of rats consuming the ID diet 
compared to the PF group (Figure 3).  Further bioinformatics analyses revealed that miR-
181d potentially targeted the mitochondrial iron transporter Slc25a37 (mitoferrin1) as 
well as the rate controlling enzyme of β-oxidation in the muscle mitochondria, carnitine 
palmitoyltransferase 1B (Cpt1b) (Figure 4A).  Importantly, the target seed recognition 
site in the 3’UTR of Slc25a37 and Cpt1b was also conserved among mice, rats, and 
humans (Figure 4B and C).   
 To validate the in silico predictions of interactions between miR-181d and the 
3’UTR of Slc25a37 and Cpt1b a reporter system was utilized.  The entire 3’UTR of 
Slc25a37 and Cpt1b were cloned into the 3’UTR of the luciferase reporter gene in pMIR-
REPORT and then co-transfected with either a mature miR-181d mimic or a negative 
control (NC) miRNA that is not predicted to regulate any known mRNA.  Interaction was 
confirmed by a significant reduction in luciferase activity.  Co-transfection with the miR-
181d mimic reduced luciferase activity of the wild type (WT) Slc25a37 and Cpt1b 
reporters by ~50% and ~40%, respectively (Figure 5A and B).  Transfection of the 
reporter construct alone or co-transfection of the reporter construct with the NC miRNA 
had no effect on Slc25a37 or Cpt1b luciferase activity (Figures 5A and B).  To 
demonstrate target specificity of miRNA-mRNA interactions, luciferase activity was 
examined in reporters containing the 3’UTR of Slc25a37 or Cpt1b with mutations in the 
predicted miR-181d seed sequences (Mutant; see table S1).  In the presence of a miR-





Figure 3  Validation of differential miR-181d expression in livers and muscles of pair-
fed (PF) and iron deficient (ID) rats by qRT-PCR.  miRNA levels were normalized to the 
small nuclear RNA, SNORD95, as the invariant control.  Numbers beneath the gene 
names indicate Cq value obtained for the PF group.  Values are shown as means ± SEM, 
















Figure 4  Species conservation of miR-181d stem-loop structure and sequence among 
mice, rats and humans (A).  Species conservation of the miR-181d seed sequence in the 

















The expression of Slc25a37 and Cpt1b mRNA was then assessed in liver and 
soleus tissue from ID and PF animals.  Although modest, the expression of Slc25a37 was 
significantly reduced in both tissues in ID animals compared to the PF control group 
(Figure 6A).  Cpt1b expression was also significantly decreased in the soleus, but not the 
liver, of ID animals compared to the PF animals (Figure 6B).  Finally, expression of the 
iron-responsive transferrin receptor  (Tfrc) mRNA was also examined for use as a 
positive control because Tfrc mRNA is stabilized in response to iron deficiency resulting 
in increased levels of transcript [9].  Tfrc mRNA expression was increased 7- and 3.5-




















Figure 5  Validation of Slc25a37 and Cpt1b as miR-181d target genes.  HEK293T cells 
were co-transfected with the pMIR-REPORT β-Gal control vector and the pMIR-
REPORT Luciferase vector containing either the wild-type (WT) or mutated (Mutant) 
3’UTR of Slc25a37 (A) or Cpt1b (B) (see Supplemental Table 1 for localization of 
predicted miR-210 binding sites and mutated sequence).  Cells were then treated with 
vehicle (Control), a miR-181d mimetic (Mimic) or a negative control (NC) miRNA with 
no known predicted mRNA targets.  After 24 h luciferase activity was measured and 
normalized to β-Galactose activity.  Experiments were performed at least three times, and 
results are presented as fold-change ± SEM of the control transfected cells.  *Statistical 















Figure 6  Expression Slc25a37 and Cpt1b mRNA in the livers (A) and muscles (B) of 
pair-fed (PF) and iron-deficient (ID) rats.  Expression of the iron-responsive transferrin 
receptor (TfRc) was assessed as a positive control.  mRNA levels were normalized to 
Cyclophilin B (Cyclo) as the invariant control.  Numbers beneath the gene names indicate 
Cq value obtained for the PF group.  Values are shown as means ± SEM, n = 8/group.  







 Three weeks on a low iron diet was sufficient to significantly reduce hemoglobin, 
hematocrit, and non-heme liver iron in the ID animals.  Although not measured in this 
study, a hemoglobin content of 80 g/L or less corresponds with significantly reduced 
muscle iron [32].  Previous studies have demonstrated that this level of iron deficiency is 
also sufficient to elicit significant metabolic effects, such as hyperglycemia and 
hyperlipidemia [25, 33].  Further, the severity of metabolic consequences associated with 
iron deficiency appears to be a graded response that progresses with decreasing 
hemoglobin levels as evidenced by an inverse correlation between hemoglobin levels and 
serum levels of lipids and glucose [34].  Changes in the abundance of mRNA involved in 
glucose and lipid metabolism in yeast and animals in response to iron deficiency suggest 
that the metabolic adaption to iron deficiency may be regulated at the level of mRNA 
expression and stability, but the contributing regulatory factors have yet to be fully 
elucidated [12, 13, 25].  
miRNA have been termed “biological rheostats” of cellular function and response 
as a result of their capacity to elicit modest, yet biologically significant, modifications in 
gene expression in response to changes in environmental cues such as developmental 
timing events and alterations in nutrient status [35-37].  In this study, the expression of 
miR-181d as a miRNA was significantly elevated in the liver and skeletal muscle as a 
result of iron deficiency.  Interestingly, the miR-181 family of miRNA was previously 
identified as being a modifier of mitochondrial function, and miR-181d in particular has 
been identified as being present in the mitochondria in mouse liver [17, 38].  In the 
present study, we examined the regulation of two previously uncharacterized miR-181d 
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mitochondrial-related targets, SLC25a37 and Cpt1b, in the liver and soleus of ID and PF 
animals.  These two tissues were selected for analysis because they are known to exhibit 
tissue-dependent responses to ID, and it was of interest to assess whether miRNA were 
integral in this tissue-dependent regulation.  
 The mitochondrial iron transporter, Slc25a37 is localized to the inner 
mitochondrial membrane and functions as an essential mitochondrial iron importer to 
support mitochondrial iron demands for heme synthesis and Fe-S cluster biogenesis [2, 
39].  Although Slc25a37 is most highly expressed in erythroid cells, it is expressed at 
detectable levels in other tissues, including both liver and skeletal muscle [2, 39].  The 
miR-181d directed down-regulation of Slc25a37 may represent a means of coordinating 
cytosolic iron availability with mitochondrial iron utilization, and therefore could play a 
critical role in coordinating cellular iron homeostasis in response to iron deficiency. 
 Questions remain however as to whether alterations in fuel utilization observed in 
ID animals are the result of a physiologic adaptation to iron deficiency, or pathologic 
consequences of insufficient iron availability.  The reduction in Cpt1b mRNA observed 
in the skeletal muscle of ID animals is consistent with a role of miR-181d in controlling 
Cpt1b expression.  In fact, the miR-181d-dependent regulation of Cpt1b may explain the 
significant reduction in skeletal muscle Cpt1b enzyme activity and diminished β-
oxidation previously observed in response to ID [40].  Additionally, miR-181d targeted 
down-regulation of Cpt1b could also contribute to the intramuscular lipid droplet 
accumulation observed in rodent models of iron deficiency [41].  Although the 
consequence of lipid accumulation in the skeletal muscle of ID animals has not been 
directly assessed, skeletal muscle lipid deposition in humans is associated with negative 
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metabolic effects, including the development of skeletal muscle insulin resistance [42, 
43].  Therefore, the therapeutic targeting and inhibiting of miR-181d to enhance Cpt1b 
activity is an intriguing possibility for the treatment of metabolic disorders associated 
with lipid accumulation and insulin resistance [44].  
Iron deficiency results in a multitude of deleterious physiological consequences, 
many of which can be directly linked to the severe negative impacts it has on skeletal 
muscle.  Indeed, skeletal muscle is one of the tissues of the body that appears to be 
particularly sensitive to iron deficiency.  As iron deficiency progresses in severity, many 
of the associated pathologic consequences slowly manifest in a graded response as iron 
stores are depleted and hemoglobin production is severely repressed.  The increased 
expression of miR-181d in response to iron deficiency in both liver and skeletal muscle 
could provide an additional mechanism that contributes to the metabolic adaption to iron 
deficiency.  The physiologic importance of miR-181d down-regulation of Cpt1b in 
response to iron deficiency is of significant interest as iron deficiency is the number one 
micronutrient deficiency worldwide, and the potential for iron deficiency to contribute to 
or to exacerbate metabolic disorders is unknown.  These findings have provided novel 
insight into metabolic adaptation to the iron deficiency and have demonstrated how 
miRNA contribute to the molecular coordination of iron homeostasis in a physiologic 
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The central hypothesis was that miRNA expression would be regulated in 
response to ID and that these changes would be associated with changes in the expression 
of target mRNA resulting in the homeostatic regulation of cellular iron metabolism.  In 
order to test this hypothesis our primary aims were to (1) examine miRNA expression 
profile under iron-adequate and iron-restricted conditions in animals, (2) to identify 
differentially expressed miRNA, (3) to examine the potential targets of differentially 
expressed miRNA, and (4) to characterize the impact of miRNA expression on putative 
targets involved in iron metabolism.  For each aim our findings were as follows: 
Aim 1:  To examine the miRNA expression profile of iron-adequate and iron-restricted 
animals. 
 Total hepatic RNA was successfully used to generate miRNA expression profiles 
from iron-adequate and iron-deficient animals.  Some 30 million qualified reads were 
generated per animal, with 34% and 25% of those reads identified as either precursor or 
mature miRNA, respectively.  More than 10 putative novel miRNA were also identified. 
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Aim 2:  To identify miRNA which are differentially expressed in response to iron 
deficiency. 
 Bioinformatic analyses of the next-generation sequencing data produced in Aim 1 
revealed more than 30 miRNA are differentially expressed in response to dietary iron 
deficiency. 
Aim 3:  To examine the potential targets of differentially expressed miRNA. 
 Hundreds of potential targets were predicted using multiple in silico target-
prediction programs.  The target list was then narrowed down to potential miR-targets 
that  are known to be intimately involved in iron metabolism and homeostasis.   
Aim 4:  To characterize the impact of miRNA expression on putative targets involved in 
iron metabolism. 
 Through the use of in vitro reporter assays we were able to confirm that the 
miRNA do directly target mRNA with important roles in the maintenance of iron 
homeostasis. 
 
 The findings from each of these aims are supportive of our initial hypothesis that 
miRNA expression is altered in response to dietary iron deficiency, and that miRNA 
contribute to the homeostatic regulation of cellular iron metabolism.  These results have 
provided insight into metabolic adaptation to iron deficiency and have demonstrated how 
miRNA contribute to the molecular coordination of iron homeostasis in a physiologic 






 The field of miRNA research is growing at an exponential rate.  Since the 
discovery of the first miRNA in worms in 1993, and the discovery of widespread species 
conservation of miRNA in the early 2000s, over 25,000 miRNA have been annotated and 
catalogued in nearly 200 different species [110].  Coinciding with the growth in miRNA 
numbers has been the growth in our knowledge and understanding of how miRNA 
themselves are regulated in addition to how they regulate target gene expression.  Thus, 
miRNA research is fraught with challenges as the technology to study miRNA regulation 
and function has hinged upon our understanding of how they work, and has rapidly 
changed over time as our understanding has developed.  Perhaps the most limiting factor 
in the current study was the lack of a high throughput technology capable of detecting the 
modest, but biologically significant, changes predicted to occur under non-pathologic 
environmental conditions, such as moderate iron deficiency [118, 131]. 
 For instance, we chose to use next-generation sequencing (NGS) to create our 
miRNA profile.  Though this technology is highly praised for its accuracy in 
distinguishing miRNA that are very similar in sequence, and its ability to detect novel 
miRNA, it is not without limitation; NGS cannot be used for absolute quantification, also 
the method of cDNA library preparation for NGS favors the capture of some miRNA 
over others, and NGS is not the most sensitive method for detecting small differences in 
miRNA expression [131, 146].  The other currently available technologies are also 
wrought with complications.  For example, miRNA microarray analysis, is fairly high-
throughput, but not as sensitive as qRT-PCR [146].  Likewise, qRT-PCR is very 
sensitive, but per sample is quite costly, and it cannot identify novel miRNA [146].  
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Thus, for our initial aim, NGS sequencing was the most appropriate currently available 
method, and even though NGS sequencing is not as sensitive for detecting differential 
miRNA expression as qRT-PCR, the results do tend to correlate very highly with results 
from downstream qRT-PCR analysis [147].   
 The fundamental determinant then for future studies will be deciding which of 
these limitations can we bypass to accurately test our hypothesis(es). Questions that still 
need to be answered include, what are the miRNA tissue-specific responses to ID, and 
what are the downstream effects of differential miRNA expression on target function and 
homeostatic iron regulation.  Additionally, it may be of interest to investigate the 
potential for therapeutic miRNA targeting for treatment of diseases of iron metabolism.  
The findings from this work demonstrate that miRNA are regulated in response to dietary 
iron deficiency, and thus have laid the groundwork for future investigations by narrowing 
the list from the thousands of existing miRNA to a much smaller pool of miRNA that 
appear to be directly affected by alterations in iron status.  A next logical step might then 
be to quantify these changes, and examine tissue specific differences in miRNA 
abundance utilizing qRT-PCR.  Furthermore, a significant amount of work remains by 
way of continuing to identify and validate the iron-related targets of these differentially 
expressed miRNA.   
 Once targets have been validated, it would then be of great usefulness to 
interrogate the functional consequences of miRNA induced changes in iron-related gene 
expression.  For instance in this study we found hepatic and skeletal muscle expression of 
miR-210 to be significantly elevated in response to dietary ID, but observed no changes 
in the expression of the miR-210 target, Iscu.  Several explanations exist for these 
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observations, and should be the subject of future investigations.  Perhaps with the 
moderate degree of ID elicited in this study, the effects on target gene expression were 
too modest to measure.  Or, perhaps the tissues in question had already adapted to the 
state of ID, and we were measuring gene expression after equilibration had been 
achieved.  Indeed, hepatic RNA binding activity of the cellular iron regulators IRP1 and 
IRP2 will begin to increase within as little as two days of placing animals on an iron 
restricted diet, and continue to increase for 10-14 days [95].  However after 2 weeks on 
an ID diet, IRP RNA binding activity tends to plateau [95].  As we only examined 
alterations in miRNA expression following 21 d of an ID diet it would be of great interest 
to assess the temporal regulation of miRNA and target mRNA expression throughout the 
progression of ID. 
 Also, because physiologic responses to miRNA regulation are often times quite 
modest, it may be necessary to over-express or inhibit miRNA expression in cells or in 
the whole-animal.  For example, cell culture-based evidence is strongly suggestive that 
miR-210 induced repression of Iscu could elicit functional consequences on Fe-S cluster 
proteins [31, 32].  While our data does not refute this evidence, it does not strongly 
support it either since no measurable changes in Iscu expression were found.  Also 
contesting this hypothesis is the fact that the effects of hypoxia and iron deficiency on 
IRP1 RNA binding activity in cultured rat liver hepatocytes elicit very different 
responses.  This suggests that miR-210 target regulation may be stimulus dependent, and 
that potential confounding factors such as ceRNA may need to be investigated. 
 To interrogate this issue further, miR-210 mimics and inhibitors could be 
transfected into cells treated with or without hypoxia, and with or without the iron 
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chelator desferrioxamine, and Iscu protein abundance could be measured.  The prediction 
would be that overexpression of miR-210 with either treatment should exacerbate the 
down-regulation of Iscu, while inhibition of miR-210 expression would decrease the 
effects on Iscu, or perhaps result in no down-regulation at all.  If this prediction was met, 
further investigation of downstream effects on Fe-S cluster proteins, such as IRP1, would 
be warranted.  If the hypothesis was not met, it would be relevant to begin to interrogate 
the factors that could interfere with miR-210/Iscu interaction, such as the simultaneous 
up regulation of other miR-210 targets that could potentially be titrating miR-210 away 
from Iscu in a stimulus-dependent manner. 
 In addition to advancing our understanding of the molecular coordination of iron 
homeostasis, many possibilities exist for exploiting both the therapeutic potential of 
miRNA for the treatment of diseases of iron metabolism and for the identification of 
plasma miRNA biomarkers that might be sensitive and timely indicators of changes in an 
individual’s iron status.  For example, mitochondrial iron overload is a prominent feature 
of human Fe-S cluster assembly disorders [46].  In this work we have demonstrated that 
the mitochondrial iron importer, Slc25a37, is targeted by the iron-regulated miR-181d.  
Future investigations might examine the potential for miR-181d to be used as a marker 
for mitochondrial iron overload.  This would be difficult though because miR-181d 
would be predicted to possibly be down-regulated in an instance of mitochondrial iron 
overload.  Therefore, it may be more warranted to investigate the therapeutic potential for 
miR-181d overexpression to protect against mitochondrial iron overload by repressing 
Slc25a37 and preventing mitochondrial iron import. 
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 In this study we have also identified the key rate limiting enzyme in muscle β-
oxidation, Cpt1a, as being directly targeted by miR-181d, therefore pharmacologic 
potential may also exist for the development of a miR-181d antagonist.  In our previous 
studies and in this most recent work we have also observed decreased Cpt1A and Cpt1b 
expression in response to dietary ID [21, 148].  Chronic systemic inhibition of CPT1 has 
been found to cause intracellular lipid accumulation and insulin resistance in rats [149].  
Interestingly, intramuscular lipid accumulation and insulin resistance have also been 
noted in rats subjected to an ID diet [21, 150].  Moreover, accumulation of triglycerides 
in skeletal muscle has also been noted in obese humans, and is thought to be a potential 
contributor to metabolic disruption and the development of insulin resistance [151, 152].  
This may be of clinical significance because ID does not affect just under-nourished 
individuals, but over-nourished individuals as well, and the potential for ID to exacerbate 
metabolic disruption has not been fully investigated [153, 154].  Intriguingly, 
overexpression of Cpt1b has previously been shown to improve insulin sensitivity in rats 
fed a high-fat diet [155].  Thus, pharmacologic inhibition of miR-181d may have 
significant therapeutic potential as a stimulator of fatty acid oxidation in skeletal muscle. 
The potential for miRNA to serve as therapeutic targets for the treatment of 
genetic disorders or for metabolic disease is quite exciting, though given the pleiotropic 
effects of altering miRNA function, it is important that we possess a more thorough 
understanding of miRNA biology and function.  In light of the progress that has been 
made over the last decade regarding miRNA expression, biogenesis, processing, and 
function, nutritional scientists are well-positioned to examine the relationship between 
nutrient status and miRNA and provide insight into mechanisms coordinating nutrient-
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gene interactions.  These studies will further our understanding of the roles miRNA play 
in coordinating the molecular response to alterations in iron status, and provide 
fundamental insights into the understanding of how iron homeostasis is maintained and 
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